Pyrrolidine derivatives as DDR inhibitors

Pyrrolidine derivatives are developed as selective DDR1 and DDR2 inhibitors with a favorable inhalation profile and low systemic exposure, addressing the need for effective treatment of fibrotic diseases by inhibiting DDR receptors with high potency and safety.

JP2024540916APending Publication Date: 2024-11-06CHIESI FARMACEUTICI SPA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024523483
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-10-19
Filing Date
2022-10-17
Publication Date
2024-11-06

AI Technical Summary

Technical Problem

There is a need for selective inhibitors of Discoidin Domain Receptors (DDR1 and DDR2) that can be administered by inhalation for treating fibrotic diseases like idiopathic pulmonary fibrosis, with a favorable inhalation profile, low metabolic stability, and minimal systemic exposure to minimize safety issues.

Method used

Development of a novel series of pyrrolidine derivatives represented by formula (I) that act as selective inhibitors of DDR1 and DDR2 receptors, exhibiting high potency, good inhalation profile, and low systemic exposure, characterized by specific structural features such as alkylene-NR A R B groups and bicyclic heteroaryl substitutions.

Benefits of technology

The pyrrolidine derivatives effectively inhibit DDR1 and DDR2 receptors with a Ki of less than 60 nM, demonstrating enhanced inhibitory activity and safety by minimizing systemic exposure, making them suitable for treating fibrotic diseases, particularly idiopathic pulmonary fibrosis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024540916000001_ABST
    Figure 2024540916000001_ABST
Patent Text Reader

Abstract

The present invention relates to a compound represented by formula (I) The present invention relates to compounds that inhibit the discoidin domain receptor of JPEG2024540916000145.jpg3998 (DDR inhibitors), methods for producing such compounds, intermediate compounds useful in the production thereof, pharmaceutical compositions containing same, and therapeutic uses thereof. The compounds of the present invention may be useful, for example, in the treatment of many disorders in which the DDR mechanism is involved.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] FIELD OF THEINVENTION The present invention relates to compounds that inhibit Discoidin Domain Receptors (DDR inhibitors), processes for producing such compounds, pharmaceutical compositions containing same and therapeutic uses thereof.

[0002] The compounds of the invention may be useful in the treatment of many disorders in which the DDR mechanism is implicated. [Background technology]

[0003] 2. Background of the Invention Discoidin domain receptors (DDRs) are type I transmembrane receptor tyrosine kinases (RTKs). The DDR family contains two distinct members, DDR1 and DDR2.

[0004] The DDR is a unique receptor among other members of the RTK superfamily in that it is activated by collagen, whereas other members of the RTK superfamily are typically activated by soluble peptide-like growth factors (see Vogel, W. (1997) Mol. Cell 1, 13-23; Shrivastava A. Mol. Cell1997; 1:25-34). Furthermore, the DDR is also unusual for RTKs because it forms a ligand-independent stable dimer that is non-covalently linked (Noordeen, NA(2006) J. Biol. Chem. 281, 22744-22751; Mihai C. J Mol Biol. 2009; 385:432-445).

[0005] The DDR1 subfamily consists of five membrane-anchored isoforms, while the DDR2 subfamily is represented by a single protein. All five DDR1 isoforms share extracellular and transmembrane domains but differ in their cytoplasmic regions (see Valiathan, RR (2012) Cancer Metastasis Rev. 31, 295-321; Alves, F. (2001) FASEB J. 15, 1321-1323).

[0006] The DDR receptor family has been implicated in a series of fibrotic diseases, including pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IDF). The first evidence of a protective role of DDR1 deletion in pulmonary fibrosis was first provided in 2006 by Dr. Vogel and his group (see Avivi-Green C, Am J Respir Crit Care Med 2006;174:420-427). The authors showed that DDR1 null mice were largely protected against bleomycin (BLM)-induced injury. Furthermore, myofibroblast expansion and apoptosis were much lower in these animals compared to their wild-type counterparts. The lack of inflammation in the knockout mice was confirmed by lavage cell counts and cytokine ELISAs. These results indicated that DDR1 expression is essential for pulmonary inflammation and fibrosis development.

[0007] DDR2 deficiency or downregulation reduces bleomycin-induced pulmonary fibrosis (see Zhao H, Bian H, Bu X, Zhang S, Zhang P, Yu J, et al Mol Ther 2016; 24:1734-1744). Zhao et al. showed that DDR2 has an important role in inducing fibrosis and angiogenesis in the lung, and in particular that DDR2 synergizes with transforming growth factor (TGF)-β in inducing myofibroblast differentiation. Furthermore, they showed that treatment of injured mice with specific siRNA against DDR2 showed therapeutic efficacy against pulmonary fibrosis. In a second publication, Jia et al. showed that mice lacking DDR2 were protected from bleomycin-induced pulmonary fibrosis (see Jia S, Am J Respir Cell Mol Biol 2018; 59:295-305). Furthermore, DDR2 null fibroblasts were significantly and much more susceptible to apoptosis than wild-type fibroblasts, supporting the paradigm that apoptosis-resistant fibroblasts are important in the progression of fibrosis.

[0008] Several compounds have been described in the literature as DDR1 or DDR2 antagonists.

[0009] Notably, neutralization of DDR receptors may be useful in the treatment of fibrosis and diseases, disorders and conditions caused by fibrosis. Moreover, neutralization of both DDR1 and DDR2 receptors may be particularly effective in the treatment of the above diseases, disorders and conditions. Summary of the Invention [Problem to be solved by the invention]

[0010] Several efforts have been made in the past few years to develop novel DDR1 and DDR2 receptor antagonists useful for the treatment of several diseases, and some of these compounds have shown efficacy in humans. Notwithstanding the above-mentioned prior literature, there remains an opportunity in the respiratory field to develop selective inhibitors of both DDR1 and DDR2 receptors, useful for the treatment of diseases or conditions associated with dysregulation of DDR receptors, in particular idiopathic pulmonary fibrosis (IPF), which are administered by inhalation route and are characterized by a good inhalation profile corresponding to good activity in the lungs, good lung retention and low metabolic stability to minimize systemic exposure and related safety issues. [Means for solving the problem]

[0011] In this direction, we have surprisingly discovered a novel series of compounds of general formula (I) shown below, which solve the problem of providing inhibitors of the receptors DDR1 and DDR2 administered by inhalation, which are active as selective inhibitors of the receptors DDR1 and DDR2 relative to other human protein kinases. Such compounds exhibit high potency, good inhalation profile, low metabolic stability, low systemic exposure, improved safety and tolerability.

[0012] Summary of the Invention In a first aspect, the present invention provides a compound of formula (I) [ka] [During the ceremony, Y is absent or -C(O)-; R 1 Ha-(C 1 -C 6 ) Alkylene-NR A R B or hydrogen; R 3 Ha-(C 1 -C 4 ) alkyl; A is A1, A2, A3 [ka] and bicyclic heteroaryl B, where * indicates the point of attachment to Y and B is R 2 is replaced by; where R 2 is H or halogen, cyano, -NR A R B , -C(O)NR A R B , -C(O)NR C -(C 1 -C 6 ) Alkylene-NR A R B , -C(O)NR C -(C 1 -C 6 ) Alkylene-OR A , -NR A C(O)R B , -OR A , -NR C -(C 1 -C 6 ) Alkylene-OR A , -NR C -(C 1 -C 6 ) Alkylene-NR A R B , -C(O)NR A -heterocycloalkyl, heterocycloalkyl, -NR A -heteroaryl, -(C 1 -C 6 ) alkylene-heterocycloalkyl, -(C 1 -C 6 ) Alkylene-OR A , -O-(C 1 -C 6 ) Alkylene-NR A R B , -O-(C 1 -C 6 ) Alkylene-OR A , -O-(C 1 -C 6 ) alkylene-heterocycloalkyl, -(C 1 -C 6 ) haloalkyl and -(C 1 -C 6 ) alkyl; R A , R B and R C is independent - (C 1 -C 6 ) alkyl or hydrogen; or R A and R B may be taken together with the nitrogen to which they are attached to form a heterocycloalkyl; And here, R 2 Each heterocycloalkyl or heteroaryl is hydrogen, halogen, -(C 1 -C 6 ) alkyl, -(C 1 -C 6 ) haloalkyl, -(C 1 -C 6 ) Alkylene-OR A , -OR A , -O-(C 1 -C 6 ) Alkylene-NR A R B and -O-(C 1 -C 6 ) Alkylene-OR A and is substituted with one or more, preferably 1 to 3, substituents independently selected from the group consisting of: and pharma- ceutically acceptable salts thereof.

[0013] In a second aspect, the present invention relates to pharmaceutical compositions comprising a compound of formula (I) and its pharma- ceutically acceptable salts in admixture with one or more pharma- ceutically acceptable carriers or excipients.

[0014] In a third aspect, the present invention relates to a compound of formula (I) and a pharma- ceutically acceptable salt or a pharmaceutical composition comprising a compound of formula (I) and a pharma- ceutically acceptable salt thereof, for use as a medicament.

[0015] In a further aspect, the present invention relates to compounds of formula (I) and pharma- ceutically acceptable salts thereof or pharmaceutical compositions comprising compounds of formula (I) and pharma- ceutically acceptable salts thereof for use in the prophylaxis and / or treatment of diseases, disorders or conditions associated with dysregulation of the DDR.

[0016] In a further aspect, the present invention relates to compounds of formula (I) and pharma- ceutically acceptable salts thereof or pharmaceutical compositions comprising compounds of formula (I) and pharma- ceutically acceptable salts thereof for use in the prophylaxis and / or treatment of fibrosis and / or diseases, disorders or conditions involving fibrosis.

[0017] In a further aspect, the present invention relates to compounds of formula (I) and pharma- ceutically acceptable salts thereof or pharmaceutical compositions comprising compounds of formula (I) and pharma- ceutically acceptable salts thereof for use in the prophylaxis and / or treatment of idiopathic pulmonary fibrosis (IPF). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0018] Detailed Description of the Invention definition Unless otherwise specified, the compounds of Formula (I) of the present invention are intended to include stereoisomers, tautomers, solvates and pharma- ceutically acceptable salts thereof.

[0019] Unless otherwise specified, the compounds of formula (I) of the present invention are intended to include compounds of formula (I)', (Ia), (Ia)', (Iaa), (Iaa)', (Iab), (Iab)', (Ib), (Ib)', (Ic), (Ic)', (Ica), (Ica)', (Id), (Id)' and (Ie).

[0020] The term "pharmaceutically acceptable salts" as used herein refers to derivatives of the compounds of formula (I) where the parent compound is suitably modified by converting free acids or basic groups, if any, into the corresponding addition salts with any base or acid that is conventionally deemed pharmaceutically acceptable.

[0021] Suitable examples of such salts include inorganic or organic acid addition salts of basic residues such as amino groups and inorganic or organic base addition salts of acidic residues such as carboxylic acid groups.

[0022] Cations of inorganic bases suitable for use in preparing salts include those of alkali or alkaline earth metals, such as potassium, sodium, calcium or magnesium.

[0023] Salts obtained by reaction of the main compound functioning as a base with inorganic or organic acids include, for example, salts of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, camphorsulfonic acid, acetic acid, oxalic acid, maleic acid, fumaric acid, succinic acid and citric acid.

[0024] The term "stereoisomers" refers to isomers of identical constitution that differ in the arrangement of their atoms in space. Enantiomers and diastereomers are examples of stereoisomers.

[0025] The term "enantiomer" refers to one of a pair of molecular species that are mirror images of each other and are not superimposable.

[0026] The terms "racemate" or "racemic mixture" refer to a composition consisting of equimolar amounts of two enantiomeric species, wherein the composition is devoid of optical activity.

[0027] As used herein, the term "halogen" or "halogen atom" or "halo" includes fluorine, chlorine, bromine, and iodine atoms.

[0028] The term “(C x -C y "(x)alkyl" (where x and y are integers) refers to a straight or branched chain alkyl group having from x to y carbon atoms. Thus, when x is 1 and y is 4, for example, the term includes methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl.

[0029] The term “(C x -C y"(x)haloalkyl" (where x and y are integers) refers to a straight or branched chain alkyl group having from x to y carbon atoms containing at least one halogen substituent. Thus, when x is 1 and y is 6, for example, the term includes, for example, CF 3 , CHF 2 and C(CH 3 ) 2 CF 3 Includes.

[0030] The term “(C x -C y )Alkylene" (where x and y are integers) refers to a divalent saturated aliphatic chain derived from an alkane having x to y carbon atoms by two hydrogen atoms from different carbon atoms; for example, methylenyl.

[0031] The term "heterocycloalkyl" refers to a saturated or partially unsaturated mono-, bi-, or spirocyclic ring system of 3 to 12 ring atoms containing one or more heteroatoms selected from N, S, or O. An example of a heterocycloalkyl is piperazinyl.

[0032] The term "spirocyclic ring system" refers to a saturated or partially unsaturated bicyclic ring system of 5 to 12 ring atoms containing one or more, e.g., 1 to 3, heteroatoms selected from N, S and O, where the two rings have only one carbon atom in common. Examples of spirocyclic ring systems are spiro[3.5]nonanyl, spiro[2.3]hexanyl, spiro[2.4]heptanyl, 2-azaspiro[3.3]heptanyl, 7-azaspiro[3.5]nonanyl, 2-oxa-6-azaspiro[3.3]heptanyl, 2-oxa-6-azaspiro[3.4]octanyl and 2-azaspiro[3.5]nonanyl.

[0033] The term "heteroaryl" refers to a mono- or bicyclic aromatic ring system containing 5-10 ring atoms and containing 1-4 or 1-3 or 1-2 heteroatoms independently selected from N, S and O, including groups having two such monocyclic rings fused through a common bond or a monocyclic ring and a monocyclic ring such as a phenyl ring linked by a single bond. Heteroaryl ring systems include pyrazolyl, furanyl, thiophenyl, oxazolyl, isoxazolyl, isothiazolyl, thiazolyl, imidazolyl, benzofuranyl, 1H-benzo[d]imidazolyl, 1H-indazolyl, benzothiophenyl, benzo[c]thiophenyl, quinazolinyl, pteridinyl, 1H-pyrazolo[5,1-c][1,2,4]triazolyl, pyrrolidinyl, indolizinyl, benzothiazolyl, pyrazolo[5,1-b]thiazolyl, 1H -imidazo[1,2-b]pyrazolyl, 1H-pyrazolo[3,4-b]pyridinyl, 1,6-dihydropyrrolo[2,3-b]pyrrolyl, 1,4-dihydropyrrolo[3,2-b]pyrrolyl, 4H-thieno[3,2-b]pyrrolyl, isobenzofuranyl, 1,2,4-triazolyl, 1,2,5-oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,5-thiadiazolyl, 1,2,3-thiadiazolyl, tetrazolyl, 6H-furo[2,3-b]pyrrolyl, 6 H-thieno[2,3-b]pyrrolyl, 4H-furo[3,2-b]pyrrolyl, benzo[d]isothiazolyl, thiazolo[4,5-b]pyridinyl, 1,3,5-triazinyl, 1,2,3,4-thiatriazolyl, 1,2,3,4-oxatriazolyl, 1,2,3,4-tetrazinyl, 1,2,4,5-tetrazinyl, 1,2,3,5-tetrazinyl, 1H-imidazo[4,5-b]pyridinyl, 7H-purinyl, 1H-pyrrolyl, 1-methyl-1H-pyrrolyl, including 1-methyl-1H-1,2,4-triazolyl, 1-methyl-1H-tetrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, imidazo[1,2-b]pyridazinyl, pyrazolo[1,5-a]pyrazinyl, imidazo[1,2-a]pyrazinyl, imidazo[1,2-a]pyrazinyl, imidazo[1,2-a]pyridinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrimidinyl and 1H-pyrrolo[2,3-b]pyridinyl.

[0034] When referring to a substituent, a dash ("-") that is not between two letters, words or symbols is meant to represent a point of attachment for such substituent.

[0035] For example, "-NH-(C 1 -C 6 ) Alkylene-OR A Any compound term such as ", ", ", ", ", ", ", ", ", ", ", ", ", ", ", ", ")") A Group, (C 1 -C 6 ) alkylene and -NH- groups, where the group ending in that order with the dash "-", in this example -NH-, is the point of attachment to the remainder of the compound of formula (I).

[0036] Carbonyl groups are preferably represented herein as -C(O)- instead of other common representations such as -CO, -(CO)- or -C(=O)-.

[0037] When a basic amino group is present in the compound of formula (I), a physiologically acceptable anion may be present, selected from chloride, bromide, iodide, trifluoroacetate, formate, sulfate, phosphate, methanesulfonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate, succinate, benzoate, p-toluenesulfonate, pamoate and naphthalenedisulfonate.Similarly, when an acidic group is present, the corresponding physiological cation may be present, including, for example, an alkali or alkaline earth metal ion.

[0038] The term "Ki" refers to the dissociation constant of the enzyme-inhibitor complex, expressed in molar units, and is an indication of the binding affinity between the inhibitor and the DDR1 or DDR2 receptor.

[0039] As indicated above, the present invention relates to a series of compounds represented by the general formula (I) detailed below, which have inhibitory activity against the receptors DDR1 and DDR2. Neutralization of the receptors DDR1 and DDR2 is particularly effective in the treatment of diseases in which DDR receptors play a role, such as fibrosis and any other diseases, disorders and conditions associated with fibrosis.

[0040] In fact, as detailed in the Examples section below, the compound of formula (I) of the present invention can act as an inhibitor of both DDR1 and DDR2 receptors in a substantial and effective manner.In particular, Table 5 below shows that the inhibitory activity of the compound of the present invention against either DDR1 or DDR2 receptor is less than 60nM in binding (expressed as Ki).This confirms that the compound of formula (I) can inhibit the two isoforms of DDR receptors that are mainly involved in fibrosis and diseases caused by fibrosis.Therefore, the compound of formula (I) can be used to treat fibrosis, especially pulmonary fibrosis, when DDR1 and DDR2 are involved.

[0041] As shown in the Examples section, Comparative Compounds section, and in particular in Table 6, the presence of a pyrrolidinyl ring in the compounds of the present invention, contrary to the comparative compound C1, which is characterized by having an aziridinyl instead of a pyrrolidinyl ring, unexpectedly and significantly determines an enhanced inhibitory activity against the DDR1 and DDR2 receptors.

[0042] Furthermore, as shown in the Examples section, the reported data are consistent with the -CH 2 Contrary to the comparative compound C2, which is characterized by a -linker, the absence of such a linker in the compounds of the invention unexpectedly and significantly determines an enhanced inhibitory activity towards the DDR1 and DDR2 receptors.

[0043] Advantageously, the compounds of the present invention have significantly higher potency than prior art compounds and can be administered to humans at lower doses, thus avoiding the adverse events that typically occur when drugs are administered at higher doses.

[0044] In addition to being remarkably high in terms of inhibitory activity against both the DDR1 and DDR2 receptors, the compounds of the present invention are also characterized by being selective inhibitors of the DDR1 and DDR2 receptors relative to other human protein kinases, by a good inhalation profile that allows them to act effectively in the pulmonary compartment, and at the same time by having a low metabolic stability that allows the minimization of drawbacks associated with systemic exposure, such as safety and tolerability issues.

[0045] Thus, the compounds of the present invention may be particularly appreciated when searching for suitable and effective compounds useful in the treatment of fibrosis, particularly idiopathic pulmonary fibrosis, that are administered by the inhalation route and are characterized by a good inhalation profile corresponding to good pulmonary activity, good pulmonary retention and low metabolic stability that minimizes systemic exposure and associated safety issues.

[0046] Thus, in one embodiment, the present invention provides a compound of general formula (I): [ka] [During the ceremony, Y is absent or -C(O)-; R 1 Ha-(C 1 -C 6 ) Alkylene-NR A R B or hydrogen; R 3 Ha-(C 1 -C 4 ) alkyl, preferably methyl; A is A1, A2, A3 [ka] and bicyclic heteroaryl B, where * indicates the point of attachment to Y and B is R 2 is replaced by; where R 2 is H or halogen, cyano, -NR A R B , -C(O)NR AR B , -C(O)NR C -(C 1 -C 6 ) Alkylene-NR A R B , -C(O)NR C -(C 1 -C 6 ) Alkylene-OR A , -NR A C(O)R B , -OR A , -NR C -(C 1 -C 6 ) Alkylene-OR A , -NR C -(C 1 -C 6 ) Alkylene-NR A R B , -C(O)NR A -heterocycloalkyl, heterocycloalkyl, -NR A -heteroaryl, -(C 1 -C 6 ) alkylene-heterocycloalkyl, -(C 1 -C 6 ) Alkylene-OR A , -O-(C 1 -C 6 ) Alkylene-NR A R B , -O-(C 1 -C 6 ) Alkylene-OR A , -O-(C 1 -C 6 ) alkylene-heterocycloalkyl, -(C 1 -C 6 ) haloalkyl and -(C 1 -C 6 ) alkyl; R A , R B and R C is independent - (C 1 -C 6 ) alkyl or hydrogen; or R A and R Bmay be taken together with the nitrogen to which they are attached to form a heterocycloalkyl; And here, R 2 Each heterocycloalkyl or heteroaryl is hydrogen, halogen, -(C 1 -C 6 ) alkyl, -(C 1 -C 6 ) haloalkyl, -(C 1 -C 6 ) Alkylene-OR A , -OR A , -O-(C 1 -C 6 ) Alkylene-NR A R B and -O-(C 1 -C 6 ) Alkylene-OR A and is substituted with one or more, preferably 1 to 3, substituents independently selected from the group consisting of: and pharma- ceutically acceptable salts thereof.

[0047] The variables Y, A, R of the compounds of formula (I) of the present invention 1 , R 2 , R 3 , R A , R B and R C All listed meanings of each are to be construed as alternatives and may be combined with each other in embodiments falling within the scope of the present invention.

[0048] Preferred halogens are themselves and -(C 1 -C 6 ) In the haloalkyl substituents, fluorine and bromine are preferred, with fluorine being more preferred.

[0049] In a preferred embodiment of the present invention, -(C 1 -C 6 )Alkylene chain is -(C 1 -C 3 ) alkylene chain.

[0050] In a preferred embodiment of the present invention, -(C1 -C 6 )Alkyl substituents are -(C 1 -C 4 ) alkyl substituents.

[0051] R 1 and R 2 are CF 3 substituted phenyl and the sole substituent of A, where R 1 and R 2 The substituent R can be attached at any available position. 1 The preferred position of the substituent R is para or meta to the -NH-C(O)- substituent. 2 Preferred locations are outlined in the embodiments of the invention as further detailed below.

[0052] In a preferred embodiment, the present invention provides a compound of formula (I)' [ka] [During the ceremony, Y is absent or -C(O)-; A is A1, A2 and A3 [ka] is selected from the group consisting of where * indicates the point of attachment to Y; R 2 is H or a halogen atom, cyano, -C(O)NH 2 , -C(O)NH-(C 1 -C 6 ) alkyl, -C(O)NH-(C 1 -C 6 ) Alkylene-NR A R B , -C(O)NH-(C 1 -C 6 ) Alkylene-OR A , -NHC(O)R B , -O-(C 1 -C 6 ) alkyl, -NH-(C 1 -C 6) Alkylene-OR A , -C(O)NH-heterocycloalkyl, heterocycloalkyl, -(C 1 -C 6 ) alkylene-heterocycloalkyl and -O-(C 1 -C 6 )alkylene-heterocycloalkyl, each of which optionally has one or more -(C 1 -C 6 ) alkyl substituted; R A Ha-(C 1 -C 6 ) alkyl; R B Ha-(C 1 -C 6 ) alkyl. R 1 is hydrogen and R 3 is methyl and its pharma- ceutically acceptable salts.

[0053] In a preferred embodiment, the invention relates to compounds of formula (I) wherein Y is absent.

[0054] In another preferred embodiment, the present invention relates to a compound represented by formula (Ia) [ka] where Y is absent and A is A1 [ka] The present invention relates to a compound of formula (I)

[0055] In a more preferred embodiment, the present invention relates to a compound of formula (Ia)' [ka] [During the ceremony, R 2 is H or a halogen atom, cyano, -C(O)NH 2 , -C(O)NH-(C1 -C 6 ) alkyl, -C(O)NH-(C 1 -C 6 ) Alkylene-NR A R B , -C(O)NH-(C 1 -C 6 ) Alkylene-OR A , -NHC(O)R B -, -O-(C 1 -C 6 ) alkyl, -NH-(C 1 -C 6 ) Alkylene-OR A , -C(O)NH-heterocycloalkyl, heterocycloalkyl, -(C 1 -C 6 ) alkylene-heterocycloalkyl and -O-(C 1 -C 6 )alkylene-heterocycloalkyl, each of said heterocycloalkyls optionally having one or more (C 1 -C 6 ) substituted with alkyl; R A Ha-(C 1 -C 6 ) alkyl; R B Ha-(C 1 -C 6 ) alkyl. R 1 is hydrogen and R 3 is methyl and pharma- ceutically acceptable salts thereof.

[0056] In another preferred embodiment, the present invention relates to a compound represented by formula (Iaa) [ka] wherein Y is absent and A is represented by [ka] The present invention relates to compounds of general formula (I),

[0057] In a more preferred embodiment, the present invention relates to a compound of formula (Iaa)' [ka] [During the ceremony, R 2 is H or a halogen atom, cyano, -C(O)NH 2 , -C(O)NH-(C 1 -C 6 ) alkyl, -C(O)NH-(C 1 -C 6 ) Alkylene-NR A R B , -C(O)NH-(C 1 -C 6 ) Alkylene-OR A , -NHC(O)R B , -O-(C 1 -C 6 ) alkyl, -NH-(C 1 -C 6 ) Alkylene-OR A , -C(O)NH-heterocycloalkyl, heterocycloalkyl, -(C 1 -C 6 ) alkylene-heterocycloalkyl and -O-(C 1 -C 6 )alkylene-heterocycloalkyl, each of which optionally has one or more (C 1 -C 6 ) alkyl substituted; R A Ha-(C 1 -C 6 ) alkyl; R B Ha-(C 1 -C 6 ) alkyl. R 1 is hydrogen and R 3 is methyl and pharma- ceutically acceptable salts thereof.

[0058] In a further preferred embodiment, the present invention provides 2is H or is selected from the group consisting of methoxy, cyano, bromo, 2-morpholinoethoxy, (4-methylpiperazin-1-yl)ethoxy, morpholinyl, 2-(dimethylamino)ethylcarbamoyl, N-methylcarbamoyl, carbamoyl, morpholinomethyl and 4-methylpiperazin-1-yl. Another preferred embodiment of the present invention relates to compounds of formula (Iaa) or (Iaa)', wherein R 2 is H or is selected from the group consisting of 2-(dimethylamino)ethoxy, 2-methoxyethylcarbamoyl, acetamido and 1-methyl-1H-3-pyrazolyl.

[0059] Most preferably, the present invention relates to at least one of the compounds of formula (Iaa) and pharma- ceutically acceptable salts thereof, as listed in Table 1 below. These compounds are particularly active at the receptors DDR1 and DDR2, as shown in Table 5.

[0060] [Table 1] [Table 2] [Table 3] [Table 4] [Table 5] [Table 6]

[0061] In another preferred embodiment, the present invention relates to a compound of formula (Iab) [ka] wherein Y is absent and A is represented by [ka] The present invention relates to compounds of general formula (I),

[0062] In a more preferred embodiment, the present invention relates to a compound of formula (Iab)' [ka] [During the ceremony, R 2 is H or a halogen atom, cyano, -C(O)NH 2 , -C(O)NH-(C 1 -C 6 ) alkyl, -C(O)NH-(C 1 -C 6 ) Alkylene-NR A R B , -C(O)NH-(C 1 -C 6 ) Alkylene-OR A , -NHC(O)R B , -O-(C 1 -C 6 ) alkyl, -NH-(C 1 -C 6 ) Alkylene-OR A , -C(O)NH-heterocycloalkyl, heterocycloalkyl, -(C 1 -C 6 ) alkylene-heterocycloalkyl and -O-(C 1 -C 6 )alkylene-heterocycloalkyl, each of which optionally has one or more (C 1 -C 6 ) alkyl substituted; R A Ha-(C 1 -C 6 ) alkyl; R B Ha-(C 1 -C 6 ) alkyl. R 1 is hydrogen and R 3 is methyl and pharma- ceutically acceptable salts thereof.

[0063] Most preferably, the present invention relates to at least one of the compounds of formula (Iab) listed in Table 1' below and pharma- ceutically acceptable salts thereof. These compounds are particularly active at the receptors DDR1 and DDR2, as shown in Table 5.

[0064] [Table 7]

[0065] In another preferred embodiment, the present invention relates to a compound represented by formula (Ib) [ka] wherein Y is -C(O)- and A is A1 [ka] The present invention relates to a compound of formula (I)

[0066] In a more preferred embodiment, the present invention relates to a compound of formula (Ib)' [ka] [During the ceremony, R 2 is H or a halogen atom, cyano, -C(O)NH 2 , -C(O)NH-(C 1 -C 6 ) alkyl, -C(O)NH-(C 1 -C 6 ) Alkylene-NR A R B , -C(O)NH-(C 1 -C 6 ) Alkylene-OR A , -NHC(O)R B , -O-(C 1 -C 6 ) alkyl, -NH-(C 1 -C 6 ) Alkylene-OR A, -C(O)NH-heterocycloalkyl, heterocycloalkyl, -(C 1 -C 6 ) alkylene-heterocycloalkyl and -O-(C 1 -C 6 ) alkylene-heterocycloalkyl, wherein each of said heterocycloalkyls is optionally substituted with heterocycloalkyl; R A Ha-(C 1 -C 6 ) alkyl; R B Ha-(C 1 -C 6 ) alkyl. R 1 is hydrogen and R 3 is methyl and pharma- ceutically acceptable salts thereof.

[0067] Most preferably, the present invention relates to the compounds of Table 2 below and their pharma- ceutically acceptable salts, which are particularly active at the receptors DDR1 and DDR2, as shown in Table 5.

[0068] [Table 8]

[0069] In another preferred embodiment, the present invention relates to a compound of formula (Ic) [ka] where Y is absent and A is A2 [ka] The present invention relates to a compound of formula (I)

[0070] In a more preferred embodiment, the present invention relates to a compound of formula (Ic)' [ka] [During the ceremony, R 2 is H or a halogen atom, cyano, -C(O)NH 2 , -C(O)NH-(C 1 -C 6 ) alkyl, -C(O)NH-(C 1 -C 6 ) Alkylene-NR A R B , -C(O)NH-(C 1 -C 6 ) Alkylene-OR A , -NHC(O)R B , -O-(C 1 -C 6 ) alkyl, -NH-(C 1 -C 6 ) Alkylene-OR A , -C(O)NH-heterocycloalkyl, heterocycloalkyl, -(C 1 -C 6 ) alkylene-heterocycloalkyl and -O-(C 1 -C 6 ) alkylene-heterocycloalkyl, wherein each of said heterocycloalkyls is optionally substituted with heterocycloalkyl; R A Ha-(C 1 -C 6 ) alkyl; R B Ha-(C 1 -C 6 ) alkyl. R 1 is hydrogen and R 3 is methyl and pharma- ceutically acceptable salts thereof.

[0071] In another preferred embodiment, the present invention relates to a compound of formula (Ica) [ka] A is represented by A2a [ka] The present invention relates to compounds of formula (Ic),

[0072] In a more preferred embodiment, the present invention relates to a compound of formula (Ica)' [ka] [During the ceremony, R 2 is H or a halogen atom, cyano, -C(O)NH 2 , -C(O)NH-(C 1 -C 6 ) alkyl, -C(O)NH-(C 1 -C 6 ) Alkylene-NR A R B , -C(O)NH-(C 1 -C 6 ) Alkylene-OR A , -NHC(O)R B , -O-(C 1 -C 6 ) alkyl, -NH-(C 1 -C 6 ) Alkylene-OR A , -C(O)NH-heterocycloalkyl, heterocycloalkyl, -(C 1 -C 6 ) alkylene-heterocycloalkyl and -O-(C 1 -C 6 ) alkylene-heterocycloalkyl, wherein each of said heterocycloalkyls is optionally substituted with heterocycloalkyl; R A Ha-(C 1 -C 6 ) alkyl; R B Ha-(C 1 -C 6 ) alkyl. R 1 is hydrogen and R 3 is methyl and pharma- ceutically acceptable salts thereof.

[0073] In a further preferred embodiment, the present invention provides2 is H, N-methylcarbamoyl, carbamoyl, cyano or acetamido.

[0074] Most preferably, the present invention relates to at least one of the compounds of formula (Ica) and pharma- ceutically acceptable salts thereof listed in Table 3 below. These compounds are particularly active at the receptors DDR1 and DDR2, as shown in Table 5.

[0075] [Table 9] [Table 10]

[0076] In another preferred embodiment, the present invention relates to a compound of formula (Id) [ka] where Y is absent and A is A3 [ka] The present invention relates to a compound of formula (I)

[0077] In a more preferred embodiment, the present invention relates to a compound of formula (Id)' [ka] [During the ceremony, R 2 is H or a halogen atom, cyano, -C(O)NH 2 , -C(O)NH-(C 1 -C 6 ) alkyl, -C(O)NH-(C 1 -C 6 ) Alkylene-NR A R B , -C(O)NH-(C 1 -C 6 ) Alkylene-OR A , -NHC(O)RB , -O-(C 1 -C 6 ) alkyl, -NH-(C 1 -C 6 ) Alkylene-OR A , -C(O)NH-heterocycloalkyl, heterocycloalkyl, -(C 1 -C 6 ) alkylene-heterocycloalkyl and -O-(C 1 -C 6 ) alkylene-heterocycloalkyl, wherein each of said heterocycloalkyls is optionally substituted with heterocycloalkyl; R A Ha-(C 1 -C 6 ) alkyl; R B Ha-(C 1 -C 6 ) alkyl. R 1 is hydrogen and R 3 is methyl and pharma- ceutically acceptable salts thereof.

[0078] Most preferably, the present invention relates to at least one of the compounds of formula (Id) and pharma- ceutically acceptable salts thereof, as listed in Table 4 below. These compounds are particularly active at the receptors DDR1 and DDR2, as shown in Table 5.

[0079] [Table 11]

[0080] In another preferred embodiment, the present invention relates to compounds of formula (Ie), wherein Y is absent and A is R as defined above. 2 The present invention relates to compounds of formula (I) wherein R is a bicyclic heteroaryl substituted with R.

[0081] More preferably, the present invention relates to at least one of the compounds of formula (Ie) listed in Table 4a below and pharma- ceutically acceptable salts thereof. These compounds are particularly active at the receptors DDR1 and DDR2, as shown in Table 5.

[0082] [Table 12]

[0083] The compounds of the present invention, including all of the compounds listed above, can be prepared from readily available starting materials by using the following general methods and procedures or by using slightly modified methods that are readily available to those of skill in the art. Although specific embodiments of the present invention are shown or described herein, those of skill in the art will recognize that all embodiments or aspects of the present invention can be obtained using the methods described herein or other known methods, reagents, and starting materials. When typical or preferred process conditions (i.e., reaction temperatures, times, molar ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used, unless otherwise indicated. Optimum reaction conditions will vary with the particular reactants or solvents used, but such conditions can be readily determined by those of skill in the art by routine optimization procedures. Thus, the methods shown below should not be considered as limiting the scope of synthetic methods available for preparing the compounds of the present invention.

[0084] In some instances, when it is necessary to mask or protect sensitive or reactive moieties in accordance with general principles of chemistry, protecting groups (PG) are used, as are commonly known (Protective groups in organic syntheses, 3rd ed. TW Greene, PGM Wuts).

[0085] Compounds of formula (I) can be prepared according to Schemes 1-5 below, which provide at least one non-limiting synthetic route to all example compounds.

[0086] In certain embodiments of the present invention, compounds of formula (I) may be prepared as depicted in Scheme 1, starting from commercially available compound (II). [ka]

[0087] In a preferred embodiment, R represented by formula (I)′ as defined above is 1 is hydrogen and R 3 Compounds of formula (I), where is methyl, may be prepared as described in Scheme 2, starting from commercially available compound (II)′. [ka]

[0088] Compounds of formula (IV) or (IV)' can be prepared from compounds of formula (II) or (II)', respectively, by conversion to acyl chloride (III) or (III)' using oxalyl chloride or thionyl chloride in a suitable solvent such as DMF or DCM, followed by amide coupling with arylamine (XI) or (XI)' using a suitable base such as DIPEA in a suitable solvent such as DCM at RT. In a different approach, compounds of formula (IV) or (IV)' can be prepared by a one-step synthesis starting from compounds of formula (II) or (II)' under suitable amide coupling reaction conditions. For example, compounds of formula (II) or (II)' and arylamine (XI) or (XI)' can be reacted with an organic base such as DIPEA or TEA in the presence of an activating agent such as HATU or TBTU in a suitable organic solvent such as DCM or DMF, typically at a temperature of about RT, for a period ranging from several hours to overnight.

[0089] Compounds of formula (V) or (V)' can be obtained from compounds of formula (IV) or (IV)' via palladium catalyzed cross-coupling of a leaving group X, where X can be a bromide or iodide. For example, the reaction can be carried out by reacting a compound of formula (IV) or (IV)' with potassium trifluoro(vinyl)borate in a suitable organic solvent such as dioxane or THF according to the classical Suzuki protocol, with potassium trifluoro(vinyl)borate in K 2 PO 4or Cs 2 CO 3 In the presence of inorganic bases such as Pd 2 (dppf)Cl 2 or other palladium source / phosphine-based ligand and reacting at elevated temperature (about 100° C.) for several hours.

[0090] The 1,3-dipolar cycloaddition may be carried out by reacting the α,β-unsaturated compound of formula (V) or (V)' with a suitable precursor such as a 1,3-dipolar or azomethine ylide, for example N-benzyl-1-methoxy-N-((trimethylsilyl)methyl)methanamine, in a solvent such as dioxane, under an acid catalyst such as TFA. The compound of formula (VI) or (VI)' may be converted to the debenzylated compound of formula (VII) or (VII)' by reduction in the presence of a suitable catalyst such as Pd / C, in a suitable solvent such as, but not limited to, EtOH or MeOH, at temperatures ranging from RT to 60°C for several hours, typically under a hydrogen atmosphere of 7-10 bar.

[0091] Compounds of formula (I) or (I)', where Y is -C(O)-, can be prepared in a one-step synthesis starting from a compound of formula (VII) or (VII)' and a carboxylic acid compound of formula (VIII) or (VIII)' under suitable amide coupling reaction conditions, in the presence of an activating agent such as HATU or TBTU, using an organic base such as DIPEA or TEA, in a suitable organic solvent such as DCM or DMF, typically at a temperature of about RT for a time ranging from a few hours to overnight.

[0092] Alternatively, a compound of formula (VII) or (VII)' can be reacted with a bromide compound of formula (X) or (X)' in a suitable organic solvent such as dioxane or toluene or DMA, with K 2 PO 4 or Cs 2 CO 3 In the presence of inorganic bases such as Pd(dba) 2Compounds of formula (I) or (I)' in which Y is absent can be converted to compounds of formula (I) or (I)' by carrying out a Buchwald cross-coupling reaction using an appropriate palladium catalyst system such as / RuPhos or other palladium source / phosphine-based ligand at various temperatures between 100-150°C for periods ranging from a few hours to overnight.

[0093] In a different approach, a compound of formula (VII) or (VII)' can be reacted with a fluoride compound of formula (IX) or (IX)' in a suitable organic solvent such as DMSO to form Cs 2 CO 3 or K 2 CO 3 In the presence of an inorganic base such as , for example, at temperatures that can vary from 80-110°C for periods ranging from a few hours to overnight, nucleophilic aromatic substitution can be carried out to convert to a compound of formula (I) or (I)' in which Y is absent.

[0094] As used herein, a compound of formula (I)' is intended to be an embodiment of a compound of formula (I). Similarly, a compound of formula (II)' or (III)' or (IV)' or (V)' or (VI)' or (VII)' or (VIII)' or (IX)' or (X)' is an embodiment of a compound of formula (II) or (III) or (IV) or (V) or (VI) or (VII) or (VIII) or (IX) or (X), respectively.

[0095] The compounds of formula (I) or (I)' contain a stereocenter which is the carbon atom of the pyrrolidine ring attached to the phenyl moiety. The compounds of formula (I) or (I)' prepared by the approach described in scheme 1 or 2, respectively, are provided as racemic mixtures. The intermediate compounds of formula (VI) or (VI)' and formula (VII) or (VII)' are provided as racemic mixtures. Separation of the racemic mixtures can be achieved by chiral resolution methods such as chiral purification. Both single enantiomers of the compounds of formula (I) or (I)' and their racemic mixtures are within the scope of the present invention.

[0096] [ka] In a different approach, as depicted in Scheme 3, intermediate compounds of formula (XV) can be obtained starting from the commercially available compound of formula (XII). Compounds of formula (XIII) can be prepared from compounds of formula (XII) via a palladium-catalyzed cross-coupling reaction. The reaction is carried out by reacting compounds of formula (XII) with potassium trifluoro(vinyl)borate in a suitable organic solvent such as dioxane with Cs according to the classical Suzuki protocol. 2 CO 3 In the presence of inorganic bases such as Pd 2 (dppf)Cl 2The 1,3-dipolar cycloaddition can be carried out by reacting the α,β-unsaturated compound of formula (XIII) with a suitable precursor such as a 1,3-dipolar or azomethine ylide, for example N-benzyl-1-methoxy-N-((trimethylsilyl)methyl)methanamine, in a suitable solvent such as dioxane, under an acid catalyst such as TFA. The resulting compound of formula (XIV) can be converted to the debenzylated compound of formula (XV) by reduction, typically under a hydrogen atmosphere of 4 bar, in the presence of a suitable catalyst such as Pd / C, in a suitable solvent such as, but not limited to, EtOH, at a temperature ranging from RT to 60° C. for several hours. The Boc-protected compound of formula (XVI) may be prepared by reacting the compound of formula (XV) with di-tert-butyl dicarbonate under basic conditions using an organic base such as TEA in a suitable solvent such as DCM. The compounds of formula (XIV), (XV) and (XVI) are provided as racemic mixtures (shown as single bonds in the schemes). The stereocenter, which is the carbon atom of the pyrrolidine ring attached to the phenyl moiety, is shown in scheme 3 with an * in the compound of formula (XVI). Separation of the racemic mixture of the compound of formula (XVI) is achieved by chiral resolution methods such as chiral purification, resulting in the compound of formula (XVI) as a single enantiomer (not shown in scheme 3). The compound of formula (XV) as a single enantiomer (shown as wavy bonds in scheme 3) can then be obtained from the single enantiomer of the compound of formula (XVI) by removing the Boc-protecting group under non-racemizing conditions, such as acidic conditions using an organic acid such as TFA.

[0097] [ka] Similarly, as depicted in Scheme 4, a compound of formula (XVII) may be prepared by reacting a compound of formula (VII) with di-tert-butyl dicarbonate under basic conditions using an organic base such as TEA in a suitable solvent such as DCM. The compound of formula (XVII) is provided as a racemic mixture (shown in the scheme as a single bond). Separation of the racemic mixture of compounds of formula (XVII) is achieved by chiral resolution methods such as chiral purification, resulting in compounds of formula (XVII) as single enantiomers (not depicted in Scheme 3). Compounds of formula (VII) as single enantiomers (shown in Scheme 4 as wavy bonds) can then be obtained from the single enantiomers of compounds of formula (XVII) by removing the Boc protecting group under non-racemizing conditions, such as acidic conditions using an organic acid such as TFA.

[0098] The compound of formula (I) or the compound of formula (I)' as a single enantiomer can then be obtained starting from the single enantiomer of the intermediate compound of formula (XV) or the single enantiomer of the intermediate compound of formula (VII), which are obtained as described above and as depicted in Scheme 3 and Scheme 4, respectively.

[0099] [ka] Similarly as described for Scheme 1, the single enantiomer of the intermediate compound of formula (XV) can be reacted with a carboxylic acid compound of formula (VIII) or a fluoride compound of formula (IX) or a bromide compound of formula (X), respectively, under the conditions described above to give the compound of formula (XVIII) as a single enantiomer. As a final step, transamination reaction of the compound of formula (XVIII) with an appropriate arylamine of formula (XI) in the presence of a strong base such as BuLi, LiHMDS or LDA in a suitable solvent such as THF gives the compound of formula (I) as a single enantiomer.

[0100] In a different approach, compounds of formula (I) as single enantiomers can be obtained from compounds of formula (VII) by reacting them with carboxylic acids of formula (VIII) or fluorides of formula (IX) or bromides of formula (X) under the conditions described for Scheme 1.

[0101] Compounds of formula (I) can be further reacted to convert functional groups to different functional groups to give other compounds of formula (I). For example, a nitrile or cyano group can be converted to an amide group in a suitable organic solvent such as DMSO in the presence of a peroxide such as hydrogen peroxide (see, for example, the preparation of compound of Example 17 from compound of Example 4).

[0102] In a different approach, the conversion of a functional group to a different functional group may be carried out as an intermediate step, for example by the participation of an intermediate compound of formula (XVII) in the preparation of a compound of formula (I) according to Scheme 5. After such conversion of a functional group, as a final step, a compound of formula (XVII) may be subjected to a transamination reaction with a suitable arylamine of formula (XI), thus providing a compound of formula (I).

[0103] Accordingly, the present invention provides a process for preparing a compound of formula (I) or a pharma- ceutically acceptable salt thereof, comprising: a) Formula (V) [ka] and N-benzyl-1-methoxy-N-((trimethylsilyl)methyl)methanamine [ka] is reacted in the presence of an acid catalyst in the presence of a solvent to obtain, for example, a compound represented by the formula (VI) [ka] [In the formula, R 1 and R 3 is as defined above. and converting the compound of formula (VI) to a compound of formula (I).

[0104] In a preferred embodiment, the method further comprises: b) Cleavage of the benzyl group of the compound of formula (VI) by reduction under a hydrogen atmosphere in the presence of a Pd catalyst to give, for example, a compound of formula (VII): [ka] to obtain a compound of; and c) reacting a compound of formula (VII) with a carboxylic acid compound of formula (VIII) or a fluoride compound of formula (IX) or a bromide compound of formula (X) to obtain, for example, a compound of formula (I).

[0105] Thus, the present invention relates to a compound of formula (VI) [ka] [In the formula, R 1 and R 3 is as defined above. The present invention provides a compound of the formula:

[0106] The present invention further provides the use of a compound of formula (VI) as defined above in the preparation of a compound of formula (I).

[0107] The present invention also relates to a compound represented by formula (VII) [ka] [In the formula, R 1 and R 3 is as defined above. The present invention provides a compound of the formula:

[0108] The present invention further provides the use of a compound of formula (VII) as defined above in the preparation of a compound of formula (I).

[0109] Thus, the present invention provides the use of a compound of formula (VI) and / or a compound of formula (VII) above in the preparation of a compound of formula (I).

[0110] The compounds of formula (I) of the present invention have surprisingly been found to effectively inhibit both the receptors DDR1 and DDR2. Advantageously, inhibition of the receptors DDR1 and DDR2 can result in effective treatment of diseases or conditions in which the DDR receptors are involved.

[0111] In this regard, the compounds of formula (I) of the present invention have antagonist drug potency, expressed as an inhibition constant Ki of 60-25 nM at DDR1 and DDR2, as shown in the Drug Efficacy Test section below. Preferably, the compounds of the present invention have been found by the present invention to have a Ki of 25-10 nM at DDR1 and DDR2. More preferably, the compounds of the present invention have a Ki of less than 10 nM at DDR1 and DDR2.

[0112] In one aspect, the present invention provides a compound of formula (I) according to any of the above disclosed embodiments for use as a medicament.

[0113] In a preferred embodiment, the present invention relates to compounds of formula (I) and pharma- ceutically acceptable salts thereof for use in the treatment of a disease, disorder or condition associated with dysregulation of the DDR.

[0114] In another aspect, the present invention relates to the compounds of formula (I) as defined above and their pharma- ceutically acceptable salts in the manufacture of a medicament for the treatment of a disorder associated with dysregulation of the DDR.

[0115] In another preferred embodiment, the present invention relates to a compound of formula (I) or a pharma- ceutically acceptable salt thereof for use in the prophylaxis and / or treatment of a disease, disorder or condition in which the DDR receptor mechanism is involved. In a more preferred embodiment, the present invention relates to a compound of formula (I) useful for the prophylaxis and / or treatment of a disease, disorder or condition in which fibrosis is involved.

[0116] As used herein, the term "fibrosis" or "fibrotic disorder" refers to a condition associated with abnormal accumulation of cells and / or fibronectin and / or collagen and / or increased recruitment of fibroblasts, including, but not limited to, fibrosis of individual organs or tissues, such as the heart, kidney, liver, joints, lung, pleural tissue, peritoneal tissue, skin, cornea, retina, musculoskeletal and gastrointestinal tract.

[0117] Preferably, the compounds of formula (I) above are useful for the treatment and / or prevention of fibrosis such as pulmonary fibrosis, idiopathic pulmonary fibrosis (IPF), liver fibrosis, renal fibrosis, ocular fibrosis, cardiac fibrosis, arterial fibrosis and systemic sclerosis.

[0118] More preferably, the compounds of formula (I) above are useful for the treatment of idiopathic pulmonary fibrosis (IPF).

[0119] In one embodiment, the present invention also relates to a method for preventing and / or treating disorders associated with the DDR receptor mechanism, comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of formula (I) as defined above.

[0120] In a further aspect, the present invention relates to the use of the compounds of formula (I) as defined above for the treatment of disorders associated with the DDR receptor mechanism.

[0121] In another aspect, the present invention relates to the use of a compound of formula (I) as defined above in the manufacture of a medicament for the treatment of a disorder associated with the DDR receptor mechanism.

[0122] In a further aspect, the present invention relates to a method for preventing and / or treating disorders or conditions associated with dysregulation of DDR receptors 1 and 2, comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of formula (I) as defined above.

[0123] In a further aspect, the present invention relates to the use of the compounds of formula (I) as defined above for the treatment of diseases, disorders or conditions associated with dysregulation of the DDR receptors 1 and 2.

[0124] As used herein, a "safe and effective amount" with respect to a compound of formula (I) or a pharma- ceutically acceptable salt thereof or other pharma- ceutical active agent means an amount of the compound that is sufficient to treat the patient's condition and low enough to avoid serious side effects, as can be routinely determined by one of skill in the art.

[0125] The compounds of formula (I) may be administered once or in a regimen in which they are administered several times over a period of time at various intervals.Typical daily dosages may vary depending on the route of administration selected.

[0126] The present invention also relates to a pharmaceutical composition comprising at least a compound of formula (I) according to any of the embodiments in admixture with one or more pharma- ceutically acceptable carriers or excipients.

[0127] In certain embodiments, the present invention relates to a pharmaceutical composition comprising a compound of formula (I) in admixture with one or more pharma- ceutically acceptable carriers or excipients, such as those described in Remington's Pharmaceutical Sciences Handbook, XVII Ed., Mack Pub., NY, USA.

[0128] Administration of the compounds of the present invention and pharmaceutical compositions thereof can be accomplished, for example, orally, nasally, parenterally (subcutaneous, intravenous, intramuscular, intrasternal and infusion) and by inhalation, depending on the needs of the patient.

[0129] Preferably, the compounds of the present invention are administered orally or by inhalation.

[0130] In certain preferred embodiments, the pharmaceutical compositions comprising the compounds of formula (I) are solid oral dosage forms such as tablets, gelcaps, capsules, caplets, granules, lozenges and bulk powders.

[0131] In certain embodiments, the pharmaceutical composition comprising a compound of Formula (I) is a tablet.

[0132] The compounds of the present invention may be administered alone or in combination with various pharma- ceutically acceptable carriers, diluents (e.g., sucrose, mannitol, lactose, starch) and additives including suspending agents, solubilizing agents, buffers, binders, disintegrating agents, preservatives, coloring agents, flavoring agents, lubricants, and the like.

[0133] In further embodiments, the pharmaceutical compositions comprising the compounds of formula (I) are liquid oral dosage forms, such as aqueous and non-aqueous solutions, emulsions, suspensions, syrups and elixirs. Such liquid dosage forms may also contain suitable known inert diluents, such as water, as well as suitable known additives, such as preservatives, wetting agents, sweeteners, flavoring agents, and agents for emulsifying and / or suspending the compounds of the invention.

[0134] In a further embodiment, the pharmaceutical composition comprising a compound of formula (I) is an inhalable formulation, such as an inhalable powder, a propellant-containing metered dose aerosol or a propellant-free inhalable formulation.

[0135] For administration as a dry powder, single or multi-dose inhalers known from the prior art may be used, in which case the powder may be filled into gelatin, plastic or other capsules, cartridges or blister packs or reservoirs.

[0136] Diluents or carriers which are chemically inert to the compounds of the invention, such as lactose or any other additive suitable for improving the inhalable fraction, may be added to the powdered compounds of the invention.

[0137] Inhalation aerosols containing a propellant gas, such as hydrofluoroalkanes, may contain the compounds according to the invention in solution or in dispersed form. Propellant-driven formulations may also contain other ingredients, such as cosolvents, stabilizers and, if desired, other additives.

[0138] Propellant-free inhalation formulations containing the compounds of the invention may be in the form of solutions or suspensions in aqueous, alcoholic or hydroalcoholic vehicles and may be delivered from jet or ultrasonic nebulizers or soft mist nebulizers known from the prior art.

[0139] The compounds of the invention may be administered as the sole active agent or in combination with other pharma- ceutical active ingredients.

[0140] The dosage of the compounds of the present invention will depend on a variety of factors, including the particular disease being treated, the severity of the condition, the route of administration, and the like, among others.

[0141] The present invention also relates to a device containing a pharmaceutical composition comprising a compound of formula (I) of the present invention in the form of a single or multiple dose dry powder inhaler or a metered dose inhaler.

[0142] All of the preferred groups or embodiments described above for compounds of formula (I) may be applied mutatis mutandis in combination with one another.

[0143] Various aspects of the invention described herein are illustrated by the following examples, which are not intended to limit the invention in any way. EXAMPLES

[0144] Embodiment Part Chemical names of compounds are given by Structure To Name Place IUPAC by PerkinElmer ChemDraw Professional 19.1.1.21. All reagents for which the synthesis method is not described in the embodiment section are commercially available or are known compounds or can be prepared by those skilled in the art from known compounds by known methods.

[0145] In the methods below, some of the starting materials are identified by an "Intermediate" or "Example" number and step number designation, which is provided solely as an aid to the practitioner skilled in the art.

[0146] "Analogous" or "similar" methods mean that such methods may include minor modifications, such as reaction temperatures, amounts of reagents / solvents, reaction times, work-up conditions, or chromatographic purification conditions.

[0147] Abbreviation TEA = triethylamine; CV = column volume; DMF = dimethylformamide; DMA = dimethylacetamide; Et 2 O = diethyl ether; THF = tetrahydrofuran; DCM = dichloromethane; ACN = acetonitrile; MeOH = methyl alcohol; EtOH = ethanol; tBu = tert-butyl; EtOAc = ethyl acetate; Boc = tert-butyloxycarbonyl; rt / RT = room temperature; LC-MS = liquid chromatography / mass spectrometry; MW = microwave; SCX = solid cation exchange; DMSO-d 6 = deuterated dimethyl sulfoxide; SFC = supercritical fluid chromatography; CDCl 3 = deuterated chloroform; NMR = nuclear magnetic resonance; DIPEA = diisopropylethylamine; HCOOH = formic acid; TBTU = O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate; UPLC = ultra performance liquid chromatography; Pd(dppf)Cl 2 = [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II);RuPhos = 2-dicyclohexylphosphino-2',6'-diisopropoxybiphenyl;BINAP = 2,2'-bis(diphenylphosphino)-1,1'-binaphthalene;t R = retention time; Pd(dba) 2= bis(dibenzylideneacetone)palladium(0);STAB = sodium triacetoxyborohydride;AcOH = acetic acid;FCC = flash column chromatography;SM = starting material;eq = equivalents;ee = enantiomeric excess;h = hours;min = minutes;Pd-171 = RuPhosPd(crotyl)Cl;Pd-170 = Pd(crotyl)(XPhos)Cl;XPhos = 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl: XPhos Pd G3 = (2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) methanesulfonate;H 2 O 2 = Hydrogen peroxide.

[0148] General Experiment Details NMR characterization: 1 H NMR spectra were recorded on a Varian MR-400 spectrometer operating at 400 MHZ (proton frequency) equipped with a self-shielded Z-gradient coil 5 mm 1H / nX broadband probehead for inverse detection, a deuterium digital lock channel unit, and a quadrature digital detection unit with transmitter offset frequency shift. Chemical shifts are reported as δ values ​​(ppm) relative to tetramethylsilane (TMS) as an internal standard. Coupling constants (J values) are given in Hertz (Hz) and multiplicities are reported using the following abbreviations (s=singlet, d=doublet, t=triplet, q=quartet, dd=doublet of doublets, dt=doublet of triplets, m=multiplet, br=broad, nd=not determined).

[0149] LC / UV / MS analysis method LC / MS retention times are estimated subject to experimental error of ±0.5 min.

[0150] Method 1: Acquity CSH C18 column 50 mm x 2.1 mm 1.7 μm, maintained at 40 °C; Mobile phase: 1% to 99.9% eluent B (MeCN / water 95:5 + 0.05% HCOOH) in eluent A (water / MeCN 95:5 + 0.05% HCOOH) within 1.5 min. Flow rate: 1 mL / min. Wavelength: 210-400 nm DAD. UPLC+Waters TM PDA+Waters TM QDA.

[0151] Method 2: Acquity CSH C18 column 50 mm x 2.1 mm 1.7 μm, maintained at 40 °C; Mobile phase: 1% to 99.9% eluent B (MeCN / water 95:5 + 0.05% HCOOH) in eluent A (water / MeCN 95:5 + 0.05% HCOOH) within 3.5 min. Flow rate: 1 mL / min. Wavelength: 210-400 nm DAD. UPLC+Waters TM PDA+Waters TM QDA.

[0152] Method 3: Waters TM Acquity QSM, Acquity UPLC CSH C18 column 50 mm × 2.1 mm 1.7 μm, maintained at 50 °C; mobile phase: eluent A (HCOONH 4 0.025M pH3), eluent B (ACN+0.1% FA). Gradient mode: 0-5.50 min, increase eluent B from 20% to 80%, 5.50-7.50 min, maintain at 80%, 7.50-8 min, decrease from 80% to 20%, maintain at 20% from 8 min to the end of 10 min. Flow rate: 0.35mL / min. Wavelength: 210-400nm DAD. UPLC+Waters TM PDA+Xevo TQS MS instrument.

[0153] Method 4: Waters TM Acquity QSM, Kinetex C8 column 100 mm x 2.1 mm 1.7 μm, maintained at 55 °C; mobile phase: eluent A (HCOONH 40.025M pH3), eluent B (ACN+0.1% FA). Gradient mode: 0-3 min, increase eluent B from 1% to 30%, 3-6.50 min, increase from 30% to 50%, 6.50-7.50 min, increase from 50% to 80%, 7.50-8 min, maintain at 80%, 8-8.10 min, decrease from 80% to 1%, maintain at 1% until the end of 8.10 to 10 min. Flow rate: 0.5mL / min. Wavelength: 210-400nm PAD. UPLC+Waters TM PDA+Xevo TQS MS instrument.

[0154] Chiral Supercritical Fluid Chromatography (SFC) Separation Protocol Diastereomeric separation of compounds was achieved by supercritical fluid chromatography (SFC) using a Gilson Preparative LC system.

[0155] Alternatively, diastereomeric separation of compounds can be performed using Waters TM Thar Prep100 preparative SFC system (P200 CO 2 The separations were performed by supercritical fluid chromatography (SFC) using a 2545 Modifier Pump, 2998 UV / VIS Detector, 2767 Liquid Handler and Stacked Injection Module.

[0156] The two enantiomer analyses were performed on the final reconstituted samples.

[0157] Supercritical fluid chromatography-mass spectrometry analysis conditions Method 5: SFC-MS was performed on a Gilson preparative LC system (Gilson Pump-333; Gilson 151; Gilson Valvemate 6 position) using a Reprosil AMS (20 mm × 250 mm, 5 μm) column with isocratic runs (20:80 MeOH:CO 2 (0.2% v / v NH 3 ), flow rate 50 mL / min, BPR 100 BarG, detector wavelength 210 nm, injection volume 1500 μL (213 mg), and column temperature 40° C.

[0158] Method 6: SFC-MS was performed on a Gilson preparative LC system using an AMS (4.6 mm × 250 mm, 5 μm) column with isocratic runs (20:80 MeOH:CO 2 (0.2% v / v NH 3 ), detector wavelength 210-400 nm, injection volume 1.0 μl, BPR 125 BarG, 4 mL / min, and column temperature 40° C.

[0159] Method 7: Acquity BEH C18 (2.1 mm × 50 mm, 1.7 μm), maintained at 60 °C; flow rate 1.0 mL / min; detector wavelength 220-300 nm; injection volume 1.0 μL; mobile phase eluent B MeCN eluent A water (0.1% v / v TFA) from 2% to 98% within 2 min. Flow rate: 1 mL / min. Wavelength: 220-300 nm.

[0160] Method 8: Acquity UPLC BEH Shield RP18 column, 100 x 2.1 mm, 1.72 μm (PlusGuard cartridge), maintained at 40 °C. Mobile phase: aqueous MeCN + 10 nM ammonium bicarbonate, 5% to 95% within 5.6 min. Flow rate: 0.4 mL / min. Wavelength: 210-400 nm DAD. UPLC+Waters TM DAD+Waters TM SQD2, single quadrupole UPLC-MS.

[0161] Method 9: Acquity UPLC HSS C18 column, 100 x 2.1 mm, 1.8 μm (PlusGuard cartridge), maintained at 40 °C. Mobile phase: 5% to 95% MeCN (0.1% formic acid) in water (0.1% formic acid) in 5.6 min. Flow rate: 0.4 mL / min. Wavelength: 210-400 nm DAD. UPLC+Waters TM DAD+Waters TM SQD2, single quadrupole UPLC-MS.

[0162] Method 10: SFC-MS was performed using a Waters LUX Cellulose-1 (20 x 250 mm, 5 μm) column. TM / Thar SFC and Waters TMAn isocratic run (50:50 isopropanol (NH 4 OH 0.1%):CO 2 ), flow rate 100 mL / min, 120 bar, 40° C. column temperature, DAD wavelength 265 nm.

[0163] Method 11: SFC-MS was performed on a Gilson preparative LC system (Gilson Pump-333; Gilson 151; Gilson Valvemate 6 position) using a Chiralcel OD-H (30 mm × 250 mm, 5 μm) column with isocratic runs (10:90 MeOH:CO 2 ), flow rate 180 mL / min, BPR 120 BarG, detector wavelength 237 nm, injection volume 1500 μL (135 mg), and column temperature 40° C.

[0164] Method 12: SFC-MS was performed on a Gilson preparative LC system using a Lux C1 (4.6 mm × 250 mm, 5 μm) column with an isocratic run (20:80 MeOH (0.2% v / v NH 3 ):CO 2 ), detector wavelength 210-400 nm, injection volume 1.0 mL, BPR 125 BarG, flow rate 4 mL / min, and column temperature 40°C.

[0165] Method 13: Waters TM Acquity CSH UPLC column, 2.1 x 50 mm, 1.7 μm maintained at 40 °C. Mobile phase: MeCN (0.1% formic acid) in water (0.1% formic acid), 3% to 99% in 1.5 min; flow rate: 1.0 ml / min; wavelength: 200-400 nm DAD. Acquity H-Class UPLC equipped with a PDA detector and a QDa mass spectrometer.

[0166] Method 14: Acquity BEH UPLC column, 2.1 x 50 mm, 1.7 μm, maintained at 40 °C. Mobile phase: MeCN (0.03% ammonia) in water (0.03% ammonia), 8% to 97% within 1.5 min; Flow rate: 0.8 ml / min; Wavelength: 210-400 nm DAD. Acquity H-Class UPLC with PDA detector and QDa.

[0167] IR and VCD Spectroscopy Protocols The stereochemistry of the two enantiomers of tert-butyl 3-(2-methyl-5-((3-(trifluoromethyl)phenyl)carbamoyl)phenyl)pyrrolidine-1-carboxylate was determined using vibrational circular dichroism (VCD) spectroscopy. By comparing measured VCD spectra with those simulated by computation, the absolute configuration of the enantiomeric pair can be reliably determined without prior knowledge of the relative stereochemistry. IR spectra are used to aid in the estimation of the relative stereochemistry. IR and VCD difference spectra are further used to determine the two enantiomers.

[0168] IR and VCD Spectroscopy IR and VCD were recorded at rt on a chiral IR and dual PEM spectrometer at BioTools Inc. PEM was recorded at 1400 cm -1 Optimized for 4cm -1 A resolution of 100 μL of CDCl was used throughout. 3 A solution of 7.1 mg of BaF 2 A 100 μm path length cell with windows was used. Solution spectra were recorded for 24 hours per enantiomer. Since both enantiomers were available, the spectrum of the virtual racemate was used to correct the baseline.

[0169] When the preparation of starting materials is not described, they are commercially available, known in the literature, or readily accessible to one skilled in the art using known methods. All solvents were purchased from commercial sources and used without further purification. Flash chromatography (FCC) was performed using Biotage® Isolera unless otherwise noted. TM (Gradient A:B Eluent A:H 2 O:ACN:HCOOH 95:5:0.1 Eluent B:H 2 O:ACN:HCOOH 5:95:0.1) followed by the use of SCX(NH) to obtain the free base of the product. When the use of "analogous" or "similar" methods is described, those skilled in the art will recognize that such methods may include minor modifications, such as reaction temperatures, amounts of reagents / solvents, reaction times, work-up conditions, or chromatographic purification conditions. All final compounds were obtained as the free base unless otherwise noted.

[0170] General Methods for Preparation of Intermediates and Example Compounds Preparation of intermediate 1: 4-(2-((5-bromopyridin-3-yl)oxy)ethyl)morpholine [ka] Sodium hydride mineral oil 60% (78 mg, 3.25 mmol) was added to a stirred solution of 2-morpholinoethan-1-ol (354 mg, 2.7 mmol) in ACN (7 ml) under an inert atmosphere. The reaction mixture was stirred for 1 h and then 3-bromo-5-fluoropyridine (440 mg, 2.500 mmol) was added in one portion. The reaction mixture was stirred at rt until LC-MS showed consumption of starting material. The reaction mixture was partitioned between water and DCM and the aqueous phase was re-extracted with DCM (10 ml x 2). The combined organic phase was filtered through a hydrophobic frit and then concentrated under reduced pressure to give the title compound (546 mg, 1.90 mmol, 76% yield), which was used directly in the next step. LC-MS (ESI): Method 1 t R = 0.16 min, m / z (M+1) = 288.82

[0171] The following intermediate 2 was prepared via aromatic nucleophilic substitution as described for intermediate 1, applying the corresponding bromo derivative. [Table 13]

[0172] Preparation of intermediate 3: 5-bromo-N-(2-(dimethylamino)ethyl)nicotinamide [ka] In a 20 mL vial, 5-bromonicotinic acid (200 mg, 0.990 mmol), N1,N1-dimethylethane-1,2-diamine (131 mg, 1.485 mmol) and TBTU (477 mg, 1.485 mmol) were dissolved in DCM (2 ml) and then DIPEA (0.345 ml, 1.980 mmol) was added in one portion. The solution was stirred overnight at rt. The crude was purified by filtration with saturated NH 4 Cl solution (1 x 10ml), saturated NaHCO 3 The organic layer was washed with MgSO solution (1×10 ml) and brine (1×15 mL). 4 The mixture was dried at 40° C. and evaporated under reduced pressure. The crude was purified by reverse phase FCC. The relevant fractions were combined, loaded onto an Isolute SCX-2 cartridge, washed with MeOH and the product was eluted with 2N methanolic ammonia. The residue was concentrated under reduced pressure to give the title compound (60 mg, 0.220 mmol, 22.27% yield). LC-MS (ESI): Method 1 t R = 0.21 min, m / z (M+1) = 273.78

[0173] The following intermediates 4 and 22 were prepared by applying the corresponding bromo derivatives via amide coupling as described for intermediate 3. [Table 14]

[0174] Preparation of Intermediate 5: 4-(5-bromopyridin-3-yl)morpholine [ka] In a 40 mL round-bottom flask, under nitrogen, add a solution of 3-bromo-5-fluoropyridine (300 mg, 1.705 mmol) in DMSO (2 mL), morpholine (220 mg, 2.56 mmol) and K 2 CO 3 (704 mg, 5.09 mmol). The resulting solution was stirred at 80° C. overnight and quenched with water (10 mL). The resulting solution was extracted with EtOAc (3×10 mL) and the organic layers were combined, washed with brine (2×10 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by FCC eluting with 0-50% EtOAc in heptane to give the title compound (170 mg, 0.699 mmol, 41% yield). LC-MS (ESI, m / z): Method 1 t R = 0.66 min, m / z (M+1) = 245.05

[0175] The following intermediates 6, 23-27 and 29 were prepared via aromatic nucleophilic substitution as described for intermediate 5, applying the corresponding bromo derivatives. [Table 15] [Table 16]

[0176] Preparation of intermediate 7: 4-((5-bromopyridin-3-yl)methyl)morpholine [ka] To a mixture of 5-bromonicotinaldehyde (300 mg, 1.613 mmol) in DCM (3 ml) and DMF (1 ml) was added morpholine (155 mg, 1.774 mmol), chlorotriisopropoxytitanium(IV) (841 mg, 3.23 mmol) and AcOH (291 mg, 4.84 mmol). The reaction mixture was stirred at RT for 1 h. STAB (684 mg, 3.23 mmol) was added and the reaction mixture was stirred at RT until LC-MS showed consumption of starting material. The reaction mixture was diluted with DCM and saturated NaHCO 3 (aqueous) and the mixture was filtered through a bed of Celite. The aqueous phase was extracted 2xDCM and the combined organic phases washed with saturated aqueous NaCl (aqueous), passed through a hydrophobic frit and concentrated under reduced pressure to give the title compound (92 mg, 0.358 mmol, 22.18% yield). LC-MS (ESI, m / z): Method 1 t R = 0.16 min, m / z (M+1) = 258.80

[0177] Preparation of intermediate 28: N-(5-bromopyridin-3-yl)acetamide [ka] To a solution of 5-bromopyridin-3-amine (1 g, 5.78 mmol) in DCM (30 ml) was added acetic anhydride (1.745 ml, 18.50 mmol) followed by DIPEA (2.73 ml, 15.61 mmol). The solution was stirred at rt overnight. The solution was diluted with NaHCO 3 The solution was diluted with saturated water and extracted with DCM. The organic layer was washed with MgSO 4 The crude was purified by FCC on silica gel (0-80% EtOAc in heptane) to give the title compound (1.1 g, 5.12 mmol, 88%). LC-MS (ESI, m / z): Method 1 t R = 0.56 min, m / z (M+1) = 216.83

[0178] Preparation of intermediate 30: tert-butyl (5-bromopyrimidin-2-yl)(1-methyl-1H-pyrazol-4-yl)carbamate [ka] 5-Bromo-N-(1-methyl-1H-pyrazol-4-yl)pyrimidin-2-amine (315 mg, 1.24 mmol) was dissolved in DCM (3 ml) and then a solution of Boc anhydride (0.576 ml, 2.48 mmol), TEA (0.518 ml, 3.72 mmol) and DMAP (7.57 mg, 0.062 mmol) was added. The solution was stirred at rt overnight. It was diluted with DCM (6 mL) and washed with water. Purification was carried out by FCC (0-60% EtOAc in heptane). The appropriate fractions were combined and evaporated under reduced pressure to give the desired compound (333 mg, 0.940 mmol, 76% yield). LC-MS (ESI, m / z): Method 1 t R = 0.87 min, m / z (M+1) = 355.87

[0179] The following intermediates were prepared as described in intermediate 30, applying the corresponding bromo derivatives. [Table 17]

[0180] Preparation of intermediate 33: 3-(pyrrolidin-1-ylmethyl)-5-(trifluoromethyl)aniline hydrochloride [ka] Step 1: 3-(trifluoromethyl)-5-vinyl-aniline (Intermediate 34) [ka] 3-Amino-5-bromobenzotrifluoride (2.50 g, 10.4 mmol), vinylboronic acid pinacol ester (2.10 mL, 12.5 mmol), XPhos Pd G3 (441 mg, 0.521 mmol), XPhos (497 mg, 1.04 mmol), and K 3 PO 4 A mixture of (5527 mg, 26.0 mmol) was suspended in 1,4-dioxane (45 mL) and water (5 mL). The reaction mixture was sparged with argon for 15 min and then stirred at 80 °C for 1.5 h. The reaction mixture was allowed to reach rt and partitioned between water and EtOAc. The organic phase was washed with saturated NaCl (aq) and dried (MgSO 4 ) and concentrated. The residue was purified by FCC on silica gel (0-30% EtOAc in cyclohexane) to give the desired compound (1.54 g, 79%). LC-MS (ESI, m / z): Method 13 t R = 1.45 min, m / z (M+1) = 188 1 H NMR (400 MHz, CDCl 3 ) δ 7.04 (s, 1H), 6.85 (s, 1H), 6.79 (s, 1H), 6.64 (dd, J=11.0, 17.5 Hz, 1H), 5.75 (d, J=17.5 Hz, 1H), 5.30 (d, J=11.0 Hz, 1H), 3.86 (br s, 2H)

[0181] Step 2: tert-Butyl N-[3-(trifluoromethyl)-5-vinyl-phenyl]carbamate (Intermediate 35) [ka] To a mixture of intermediate 34 (500 mg, 2.67 mmol) and di-tert-butyl dicarbonate (0.77 mL, 3.34 mmol) was added toluene (5 mL). The reaction mixture was stirred at 100° C. for 19 h, then cooled to RT and concentrated under reduced pressure. The residue was diluted with heptane, filtered and partially concentrated, resulting in the formation of a thick precipitate. The suspension was filtered under reduced pressure to give the title compound (488 mg, 64%). LC-MS (ESI, m / z): Method 14 t R = 1.76 min, m / z (M-1) = 286 1 H NMR (400 MHz, CDCl 3 ) δ 7.59 - 7.54 (m, 2H), 7.32 (s, 1H), 6.69 (dd, J=11.0, 17.5 Hz, 1H), 6.56 (s, 1H), 5.81 (d, J=17.5 Hz, 1H), 5.35 (d, J=11.0 Hz, 1H), 1.53 (s, 9H)

[0182] Step 3: tert-Butyl N-[3-formyl-5-(trifluoromethyl)phenyl]carbamate (Intermediate 36) [ka] A solution of intermediate 35 (488 mg, 1.70 mmol) in DCM (20 mL) was sparged with ozone at -78 °C for 30 min, at which point a light blue color was observed. Dimethyl sulfide (0.62 mL, 8.49 mmol) was added and the reaction mixture was warmed to rt and stirred for 1 h. The reaction mixture was concentrated under reduced pressure and the residue was purified by column chromatography on silica gel (0-20% EtOAc in cyclohexane) to give the title compound (278 mg, 57%). LC-MS (ESI, m / z): Method 14 t R = 1.60 min, m / z (M-1) = 288 1 H NMR (400 MHz, CDCl 3 ) δ 10.02 (s, 1H), 8.06 (s, 1H), 7.98 (s, 1H), 7.80 (s, 1H), 6.76 (s, 1H), 1.54 (s, 9H)

[0183] Step 4: tert-Butyl N-[3-(pyrrolidin-1-ylmethyl)-5-(trifluoromethyl)phenyl]carbamate (Intermediate 37) [ka] To a solution of intermediate 36 (140 mg, 0.484 mmol) in DCM (3.5 mL) was added pyrrolidine (440 μL, 0.532 mmol), acetic acid (83 μL, 1.45 mmol) and titanium(IV) isopropoxide (290 μL, 0.968 mmol). The reaction mixture was stirred at rt for 1 h. Sodium triacetoxyborohydride (205 mg, 0.968 mmol) was added and the reaction mixture was stirred at rt for an additional 1.5 h. The reaction mixture was diluted with saturated NaHCO 3 (aq) and EtOAc. The organic phase was washed with water then saturated NaCl (aq), filtered through a hydrophobic frit and concentrated under reduced pressure to give the title compound which was used in the next step without further purification. LC-MS (ESI, m / z): Method 14 t R = 1.75 min, m / z (M+1) = 345 1 H NMR (400 MHz, CDCl 3 ) δ 7.65 (s, 1H), 7.44 (s, 1H), 7.27 (s, 1H), 6.58 (s, 1H), 3.63 (s, 2H), 2.55 - 2.50 (m, 4H), 1.81 - 1.77 (m, 4H), 1.52 (s, 9H)

[0184] Step 5: 3-(pyrrolidin-1-ylmethyl)-5-(trifluoromethyl)aniline (Intermediate 33) To a solution of intermediate 37 (186 mg, 0.540 mmol) in MeOH (3.00 mL) was added 4M HCl in dioxane (0.41 mL, 1.62 mmol). The reaction mixture was stirred at rt overnight. The reaction mixture was concentrated under reduced pressure to give the HCl salt of the title compound (140 mg, 90%). LC-MS (ESI, m / z): Method 14 t R = 1.39 min, m / z (M+1) = 245 1 H NMR (400 MHz, DMSO-d 6) δ 10.64 (s, 1H), 7.12 (s, 1H), 6.98 (s, 1H), 6.96 (s, 1H), 4.27 (d, J=6.0 Hz, 2H), 3.37 - 3.31 (m, 2H), 3.07 - 2.98 (m, 2H), 2.03 - 1.96 (m, 2H), 1.91 - 1.86 (m, 2H)

[0185] Example 5: Preparation of 4-methyl-3-(1-(5-(2-morpholinoethoxy)pyridin-3-yl)pyrrolidin-3-yl)-N-(3-(trifluoromethyl)phenyl)benzamide [ka] Step 1: 3-Iodo-4-methylbenzoyl chloride (Intermediate 8) [ka] 3-Iodo-4-methylbenzoic acid (14.35 g, 54.8 mmol) was dissolved in DCM (100 ml) under argon atmosphere. DMF (0.085 ml) was added followed by dropwise addition of oxalyl chloride (6.95 ml, 82 mmol) at 0° C. The reaction mixture was warmed to rt and stirred under argon atmosphere for 2 h. The progress of the reaction was monitored by LC-MS (after quenching a sample with MeOH) and was completely converted after 2 h. The solvent was evaporated and the crude was used in the next step without further purification.

[0186] Step 2: 3-iodo-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide (Intermediate 9) [ka] Intermediate 8 (15.36 g, 54.8 mmol) was dissolved in THF (50 ml) and this solution was added to a solution of 3-(trifluoromethyl)aniline (6.84 ml, 54.8 mmol), 4-dimethylaminopyridine (1.338 g, 10.95 mmol) and N-ethyl-N-isopropylpropan-2-amine (11.45 ml, 65.7 mmol) in THF (50 ml). The reaction mixture was stirred at RT overnight. The mixture was concentrated under reduced pressure. The crude material was dissolved in water and extracted with DCM (x3). All the combined organic layers were washed with Na 2 SO 4 The crude material was used in the next step without further purification (100%, 54.8 mmol). 1 H NMR (300 MHz, chloroform-d) δ 8.29 (d, J = 1.9 Hz, 1H), 8.11 (s, 1H), 7.94 (d, J = 1.9 Hz, 1H), 7.87 (dt, J = 8.1, 1.7 Hz, 1H), 7.75 (dd, J = 7.9, 1.9 Hz, 1H), 7.47 (t, J = 7.9 Hz, 1H), 7.40 (d, J = 7.7 Hz, 1H), 7.32 (d, J = 7.9 Hz, 1H), 2.48 (s, 3H)

[0187] Step 3: 4-Methyl-N-(3-(trifluoromethyl)phenyl)-3-vinylbenzamide (Intermediate 10) [ka] An oven-dried 400-mL reactor was charged with intermediate 9 (15 g, 37.0 mmol), potassium trifluoro(vinyl)borate (5.95 g, 44.4 mmol), K 2 CO 3 (10.23 g, 74.0 mmol) was charged and 1,4-dioxane (150 ml) was added via syringe under an argon atmosphere. The solution was flushed with argon (10 min) and then Pd(dppf)Cl 2(0.361 g, 0.494 mmol) was added. The tube was sealed and heated at 110° C. for 18 h. The reaction mixture was filtered through a pad of Celite and dried under reduced pressure. The residue was dissolved in 200 mL of AcOEt and NH 4 Cl (1 × 100 ml), NaHCO 3 (1×100 mL) and brine (1×150 mL). The organic layer was washed with MgSO 4 The crude was purified by FCC (100:0 -> 40:60 gradient 10 CV eluent A: n-heptane eluent B: AcOEt) and the appropriate fractions were collected and dried to give the title compound (8 g, 26.2 mmol, 71%). 1 H NMR (300 MHz, DMSO-d 6 ) δ 8.03 (d, J = 1.8 Hz, 1H), 7.76 (dd, J = 7.9, 1.9 Hz, 1H), 7.33 (dt, J = 7.9, 0.7 Hz, 1H), 6.98 (dd, J = 17.5, 11.0 Hz, 1H), 5.76 (dd, J = 17.5, 1.2 Hz, 1H), 5.41 (dd, J = 11.0, 1.2 Hz, 1H), 3.84 (s, 3H), 2.37 (s, 3H)

[0188] Step 4: 3-(1-benzylpyrrolidin-3-yl)-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide (Intermediate 11) [ka] A mixture of intermediate 10 (14.00 g, 45.9 mmol), N-benzyl-1-methoxy-N-((trimethylsilyl)methyl)methanamine (10.89 g, 45.9 mmol), and 0.01% TFA (0.035 ml, 0.459 mmol) in dioxane (100 ml) was placed in a sealed vessel and heated at 120° C. for 3 h. The solvent was removed under reduced pressure. The reaction mixture was diluted with AcOEt and water. The organic layer was separated and the aqueous layer was extracted with AcOEt (2×). The combined organic layers were washed with brine and MgSO 4Drying at 40° C. and concentration gave the crude product, which was used directly in the next step or purified by direct phase FCC (heptane 100%→heptane / AcOEt=6:4) to give the title product (7 g, 16 mmol, 35% yield).

[0189] Step 5: 4-Methyl-3-(pyrrolidin-3-yl)-N-(3-(trifluoromethyl)phenyl)benzamide (Intermediate 12) [ka] A Parr reactor was purged with nitrogen and charged with palladium / C 5R39 JM 5% (4 g, 0.940 mmol, 2.5 wt%). The system was purged once more with nitrogen and placed under reduced pressure. A solution of intermediate 11 (10 g, 22.81 mmol) in MeOH (300 ml) was then charged and the system was purged once more with nitrogen. The solution was then placed under a hydrogen atmosphere (7 bar), warmed to 40±° C. and stirred for 2 h. The reaction mixture and reactor washings were filtered through Celite and concentrated to give the crude product which was used in the next step without further purification. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 10.55 (s, 1 H), 8.27 (s, 1 H), 8.10 (br d, J=8.11 Hz, 1 H), 7.99 (s, 1 H), 7.80 (dd, J=7.89, 1.75 Hz, 1 H), 7.60 (t, J=8.00 Hz, 1 H), 7.45 (d, J=7.89 Hz, 1 H), 7.37 (d, J=8.11 Hz, 1 H), 3.61 - 3.71 (m, 1 H), 3.55 (dd, J=11.07, 8.00 Hz, 1 H), 3.37 - 3.44 (m, 1 H), 3.19 - 3.26 (m, 1 H), 3.13 (dd, J=10.96, 9.21 Hz, 1 H), 2.41 (s, 3 H), 2.29 - 2.38 (m, 1 H), 1.92 - 2.05 (m, 1 H)

[0190] Step 6: 4-Methyl-3-(1-(5-(2-morpholinoethoxy)pyridin-3-yl)pyrrolidin-3-yl)-N-(3-(trifluoromethyl)phenyl)benzamide (Example 5) In a 20 mL MW vial equipped with a magnetic stir bar and a seal cap was added 4-(2-((5-bromopyridin-3-yl)oxy)ethyl)morpholine (124 mg, 0.431 mmol), Intermediate 12 (100 mg, 0.287 mmol), CsCO 3 (281 mg, 0.861 mmol), RuPhos (26.8 mg, 0.057 mmol), Pd(dppf)Cl 2 (10.50 mg, 0.014 mmol). The vessel was evacuated and back-filled with Ar, then DMA (4 ml) was added via syringe. The solution was heated to 120° C. and stirred for 2 h. The reaction mixture was filtered, the filtrate was washed with EtOH, the solution was reduced in volume under reduced pressure, and the remaining crude was purified by reversed phase FCC (gradient A:B 100:0 to 60:40 over 10 CV, eluent A:H 2 O:ACN:HCOOH 95:5:0.1 Eluent B:H 2 0:ACN:HCOOH 5:95:0.1). Relevant fractions were combined, loaded onto an Isolute SCX-2 cartridge, washed with MeOH and the product was eluted with 2N methanolic ammonia. The residue was concentrated under reduced pressure to give the title compound (11 mg, 0.020 mmol, 6.91% yield). 1H NMR (acetone, 400 MHz) δ 8.25 (s, 1H), 8.12 (s, 1H), 8.0-8.0 (m, 2H), 7.7-7.9 (m, 1H), 7.63 (dd, J=2.1, 10.0 Hz, 2H), 7.55 (t, J=8.0 Hz, 1H), 7.41 (d, J=7.7 Hz, 1H), 7.36 (d, J=7.9 Hz, 1H), 6.51 (t, J=2.1 Hz, 1H), 4.16 (t, J=5.8 Hz, 2H), 3.8-3.9 (m, 1H), 3.77 (t, J=8.4 Hz,1H), 3.5-3.6 (m, 6H), 3.4-3.5 (m,1H), 3.37 (t, J=8.7 Hz, 1H), 2.72 (t, J=5.7 Hz, 3H), 2.5-2.4 (m, 1H), 2.3-2.2 (m, 1H), 2.23-2.50 (m, 6H) LC-MS (ESI): Method 4t R = 5.36 minutes; m / z (M+1) = 555.2;

[0191] The following compounds were prepared by the methods described in Example 5, steps 1-6, applying the corresponding, commercially available bromo-intermediate in step 6; such methods may include minor modifications, such as reaction temperature, reaction time, and work-up conditions. In some cases, the catalyst, ligand (e.g., Pd(dppf)Cl 2 / Pd(dba) instead of RuPhos 2 / BINAP) or solvent were modified, such changes are noted in the tables. [Table 18] [Table 19] [Table 20] [Table 21] [Table 22]

[0192] Example 13: Preparation of 3-(1-(5-bromopyridin-3-yl)pyrrolidin-3-yl)-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide [ka] Step 1: 3-(1-(5-bromopyridin-3-yl)pyrrolidin-3-yl)-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide 3-Bromo-5-fluoropyridine (672 mg, 3.82 mmol) and intermediate 12 (133 mg, 0.382 mmol) were dissolved in DMSO (2 ml) and the resulting solution was mixed with Cs 2 CO 3 (249 mg, 0.764 mmol) was added in one portion. The mixture was stirred for 72 h at 80 °C. The crude was diluted with 50 mL of brine, the solution was extracted with THF, and the organic layer was washed with MgSO 4 Drying at 40° C. and filtration under reduced pressure gave the crude material which was purified by silica gel FCC (EtOAc in n-heptane 100:0→0:100) to give the title product (173 mg, 0.343 mmol, 90% yield). 1 H NMR (acetone, 400 MHz) δ 9.73 (br s, 1H), 8.25 (s, 1H), 8.0-8.1 (m, 3H), 7.90 (s, 1H), 7.83 (dd, 1H, J=1.8, 7.9 Hz), 7.57 (t, 1H, J=8.0 Hz), 7.43 (d, 1H, J=7.5 Hz), 7.38 (d, 1H, J=7.9 Hz), 7.12 (t, 1H, J=2.2 Hz), 3.91 (br d, 1H, J=8.1 Hz), 3.8-3.9 (m, 1H), 3.6-3.7 (m, 1H), 3.5-3.6 (m, 1H), 3.42 (t, 1H, J=8.8 Hz), 2.52 (s, 3H), 2.4-2.5 (m, 1H), 2.32 (br d, 1H, J=9.4 Hz) LC-MS ESI): Method 4t R = 6.04 minutes; m / z (M+1) = 505.07

[0193] The following compounds were prepared as described in Example 13, step 1. [Table 23]

[0194] The following intermediate was prepared as described in Example 13, step 1. [Table 24]

[0195] Example 14: Preparation of 4-methyl-3-(1-nicotinoylpyrrolidin-3-yl)-N-(3-(trifluoromethyl)phenyl)benzamide [ka] Step 1: 4-Methyl-3-(1-nicotinoylpyrrolidin-3-yl)-N-(3-(trifluoromethyl)phenyl)benzamide Nicotinoyl chloride hydrochloride (38.3 mg, 0.215 mmol) was dissolved in pyridine (2 ml), then intermediate 12 (75 mg, 0.215 mmol) was added and the mixture was stirred at RT overnight. To the reaction mixture was added water and DCM. The mixture was stirred for 10 min and then the phases were separated. The aqueous layer was extracted using DCM (3×). The combined organic layers were washed with 5% aqueous citric acid, 2×, saturated NaHCO 3 The combined organic phase was washed with Na 2 SO 4 Drying at 40° C. and then evaporation gave a residue which was purified by reversed phase FCC (gradient A:B 100:0 to 60:40 in 10 CV, eluent A:H 2 O:ACN:HCOOH 95:5:0.1 Eluent B:H 2The mixture was purified with 5:95:0.1 hexanes (5:O:ACN:HCOOH). The relevant fractions were combined, loaded onto an Isolute SCX-2 cartridge, washed with MeOH and the product was eluted with 2N methanolic ammonia. The residue was concentrated under reduced pressure to give the title compound (32 mg, 0.071 mmol, 32.8% yield). 1 H NMR (acetone, 400 MHz) δ 9.6-9.9 (m, 1H), 8.78 (s, 1H), 8.62 (br dd, J=3.6, 15.7 Hz, 1H), 8.26 (br s, 1H), 7.9-8.2 (m, 3H), 7.80 (br dd, J=7.9, 18.6 Hz, 1H), 7.57 (br t, J=7.6 Hz, 1H), 7.2-7.5 (m, 3H), 3.54 - 4.15 (m, 5H), 2.51 (s, 2H), 2.09-2.40 (m, 3H) LC-MS (ESI): Method 1 t R = 1.05 min; m / z (M+1) = 454.12

[0196] Example 15 and Example 16: Preparation of (R)-4-methyl-3-(1-(pyridin-3-yl)pyrrolidin-3-yl)-N-(3-(trifluoromethyl)phenyl)benzamide and (S)-4-methyl-3-(1-(pyridin-3-yl)pyrrolidin-3-yl)-N-(3-(trifluoromethyl)phenyl)benzamide [ka] Step 1: tert-Butyl 3-(2-methyl-5-((3-(trifluoromethyl)phenyl)carbamoyl)phenyl)pyrrolidine-1-carboxylate (Intermediate 13) [ka] To a solution of intermediate 12 (6.40 g, 18.37 mmol) in DCM (150 ml) at rt was added di-tert-butyl dicarbonate (4.81 g, 22.05 mmol). The reaction mixture was stirred overnight at rt and then concentrated under reduced pressure. The residue was purified by FCC (0-30% EtOAc in n-heptane) to give the title compound (3.93 g, 8.76 mmol, 47.7% yield). 1 H NMR (acetone, 400 MHz) δ 9.76 (br s, 1H), 8.26 (s, 1H), 8.04 (d, J=8.1 Hz, 1H), 7.97 (s, 1H), 7.79 (d, J=7.5 Hz, 1H), 7.57 (t, J=8.0 Hz, 1H), 7.42 (d, J=7.7 Hz, 1H), 7.33 (d, J=7.9 Hz, 1H), 3.5-3.8 (m, 3H), 3.2-3.4 (m, 2H), 2.46 (s, 3H), 2.2-2.3 (m, 1H), 2.04-2.10 (m, 1H), 1.45 (s, 9H) LC-MS (ESI): Method 2t R = 2.67 minutes; m / z (M+1-tBu) = 393.0

[0197] Step 2: tert-Butyl 3-(2-methyl-5-((3-(trifluoromethyl)phenyl)carbamoyl)phenyl)pyrrolidine-1-carboxylate (Intermediate 14) [ka] Intermediate 13 (3.93 g, 8.76 mmol) as a racemic mixture was dissolved in a 142 mg / mL solution in MeOH and then purified by chiral FC by method 5. The fractions of the first eluting enantiomer were then combined and evaporated to near dryness using a rotary evaporator. The resulting solid was then transferred to a final vessel with MeOH, which was removed under a stream of compressed air at 35° C. and then stored in a vacuum oven at 35° C. and 5 mbar until constant weight to give the title compound (250 mg, 0.557 mmol). Chiral analysis (SFC method 6): R 1.16min, ee 100% LC-MS (ESI): Method 7t R = 1.79 min; m / z (M+1-tBu)= 393.3 IR and VCD spectroscopy: The configuration R was determined.

[0198] Step 3: tert-Butyl 3-(2-methyl-5-((3-(trifluoromethyl)phenyl)carbamoyl)phenyl)pyrrolidine-1-carboxylate (Intermediate 15) [ka] The same chiral FC separation was carried out according to step 2 and the combined fractions of the second eluting enantiomer were evaporated to give the title compound (1.88 g). Chiral analysis (SFC method 6): R 2.46 minutes, ee 99.8% LC-MS (ESI): Method 7t R = 1.79 min; m / z (M+1- tBu)= 393.3 IR and VCD spectroscopy: The configuration S was determined.

[0199] Step 4: (R)-4-Methyl-3-(pyrrolidin-3-yl)-N-(3-(trifluoromethyl)phenyl)benzamide 2,2,2-trifluoroacetate (Intermediate 16) [ka] Intermediate 14 (250 mg, 0.557 mmol) was placed in a 40 mL vial, and then trifluoroacetic acid (500 μl, 6.49 mmol) was added dropwise. The mixture was stirred at rt for 10 min. EtOH was added and the solvent was evaporated under reduced pressure to give the desired product without further purification (215 mg, 0.557 mmol, 100% yield).

[0200] Step 5: (S)-4-Methyl-3-(pyrrolidin-3-yl)-N-(3-(trifluoromethyl)phenyl)benzamide 2,2,2-trifluoroacetate (Intermediate 17) [ka] Starting from intermediate 15, the method described in step 4 was followed to give the title product (250 mg, 0.541 mmol, 95% yield).

[0201] Step 6: (R)-4-Methyl-3-(1-(pyridin-3-yl)pyrrolidin-3-yl)-N-(3-(trifluoromethyl)phenyl)benzamide (Example 15) Intermediate 16 (60 mg, 0.156 mmol) and 3-bromopyridine (37.0 mg, 0.234 mmol) were reacted as described in Example 5, step 6 to give the title compound (20.3 mg, 0.048 mmol, 30.6% yield). 1 H NMR (ACN-d3, 400 MHz) δ 8.88 (br s, 1H), 8.14 (s, 1H), 8.03 (d, J=2.8 Hz, 1H), 7.8-7.9 (m, 3H), 7.73 (dd, J=1.9, 8.0 Hz 1H), 7.54 (t, J=8.0 Hz, 1H), 7.43 (d, J=7.9 Hz, 1H), 7.37 (d, J=7.9 Hz, 1H), 7.16 (dd, J=4.6, 8.6 Hz, 1H), 6.95 (ddd, J=1.3, 3.0, 8.4 Hz, 1H), 3.86 (dd, J=7.2, 9.0 Hz, 1H), 3.7-3.8 (m, 1H), 3.4-3.6 (m, 3H), 2.49 (s, 3H), 2.4-2.5 (m, 1H), 2.2-2.3 (m, 1H) LC-MS (ESI): Method 4t R = 5.40 minutes; m / z (M+1) = 426.29

[0202] Step 7: (S)-4-Methyl-3-(1-(pyridin-3-yl)pyrrolidin-3-yl)-N-(3-(trifluoromethyl)phenyl)benzamide (Example 16) Intermediate 17 (70 mg, 0.151 mmol) and 3-bromopyridine (36.0 mg, 0.227 mmol) were reacted as described in Example 5, step 6 to give the title compound (43.2 mg, 0.090 mmol, 59.9% yield). 1 H NMR (ACN-d3, 400 MHz) δ 8.91 (br s, 1H), 8.15 (s, 1H), 8.02 (d, J=2.9 HzM, 1H), 7.8-7.9 (m, 3H), 7.73 (dd, J=1.5, 7.9 Hz, 1H), 7.54 (t, J=8.0 Hz, 1H), 7.43 (d, J=7.9 Hz, 1H), 7.37 (d, J=8.1 Hz, 1H), 7.18 (dd, J=4.7, 8.4 Hz, 1H), 6.98 (dd, J=2.4, 8.1 Hz, 1H), 3.8-3.9 (m, 1H), 3.7-3.8 (m, 1H), 3.4-3.6 (m, 3H), 2.49 (s, 3H), 2.4-2.5 (m, 1H), 2.1-2.4 (m, 1H) LC-MS (ESI): Method 3t R = 3.82 minutes; m / z (M+1) = 426.20

[0203] The following compounds were prepared as described in Example 5, step 6 using the corresponding commercially available or synthesized bromo intermediates. The methods used were subject to minor modifications, such as reaction temperature, reaction time, work-up conditions, and in some cases catalysts, ligands (e.g., Pd(dppf)Cl 2 / Pd-171 instead of RuPhos) or solvent (dioxane instead of DMA). [Table 25] [Table 26] [Table 27] [Table 28] [Table 29] [Table 30] [Table 31] [Table 32]

[0204] The following intermediates and / or examples were prepared as described in Example 5, Step 6. [Table 33] [Table 34]

[0205] Example 17: Preparation of 5-(3-(2-methyl-5-((3-(trifluoromethyl)phenyl)carbamoyl)phenyl)pyrrolidin-1-yl)nicotinamide [ka] Step 1: 5-(3-(2-methyl-5-((3-(trifluoromethyl)phenyl)carbamoyl)phenyl)pyrrolidin-1-yl)nicotinamide A round-bottom flask was charged with the compound of Example 4 (30 mg, 0.067 mmol) and K 2 CO 3 (33.5 mg, 0.243 mmol) was added and then flushed with argon. DMSO (0.50 ml) was added, followed by 30 wt% H 2 O 2Aqueous solution (8.99 μl, 0.088 mmol) was added dropwise. The reaction mixture was stirred at rt for 2 h. Water (10 mL) and AcOEt (15 mL) were added, the reaction was stirred for 15 min, the layers were separated and the aqueous layer was extracted again with AcOEt (2×10 mL). The organic layers were combined and washed with Na 2 SO 4 The crude material was purified by FCC on silica gel (DCM / MeOH 100:7 to 10:1) to give the title product, which was purified again by FCC (NH column 28 g, DCM / MeOH 95:5) to give the title compound (9 mg, 0.019 mmol, 28.8% yield). 1 H NMR (acetone, 400 MHz) δ 9.83 (br s, 1H), 8.41 (br s, 1H), 8.27 (s, 1H), 8.0-8.2 (m, 3H), 7.83 (dd, J=1.8, 7.9 Hz, 1H), 7.52 - 7.60 (m, 2H), 7.3-7.5 (m, 3H), 6.72 (br s, 1H), 3.8-3.9 (m, 2H), 3.66 (dt, J=3.1, 8.8 Hz, 1H), 3.5-3.6 (m, 1H), 3.43 (t, J=8.7 Hz, 1H), 2.52 (s, 3H), 2.48 (ddd, J=3.1, 6.1, 12.5 Hz, 1H), 2.2-2.4 (m, 1H) LC-MS ESI): Method 4t R = 6.08 min; m / z (M+1) = 469.2

[0206] The following compounds were obtained as single enantiomers or racemic mixtures using the corresponding intermediates as described in Example 17, step 1; such methods may include minor modifications such as reaction temperature, amounts of reagents / solvents, reaction times, work-up and chromatographic purification conditions (e.g., SCX only). [Table 35]

[0207] Example 47: Preparation of (S)-3-(1-(6-((1-(2-methoxyethyl)-1H-pyrazol-4-yl)amino)pyridin-3-yl)pyrrolidin-3-yl)-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide [ka] Intermediate 39 (53 mg, 0.080 mmol) was dissolved in trifluoroacetic acid (1 ml, 12.98 mmol) and the mixture was stirred for 1 h at rt. 2M NaOH (7.5 mL) and DCM were added. The organic layer was separated and washed with Na 2 SO 4 After evaporation, the title compound (33 mg, 0.06 mol, 73% yield) was obtained. 1 H NMR (DMSO-d 6 , 400 MHz) δ 10.38 (s, 1H), 8.18 (s, 1H), 8.12 (s, 1H), 8.00 (br d, 1H, J=8.1 Hz), 7.90 (d, 1H, J=1.5 Hz), 7.84 (s, 1H), 7.75 (dd, 1H, J=1.8, 7.9 Hz), 7.5-7.6 (m, 2H), 7.40 (d, 1H, J=7.7 Hz), 7.3-7.4 (m, 2H), 6.99 (dd, 1H, J=2.8, 9.0 Hz), 6.59 (d, 1H, J=8.8 Hz), 4.14 (t, 1H, J=5.4Hz), 3.6-3.7 (m, 1H), 3.6-3.6 (m, 3H), 3.38-3.48 (m, 1H), 3.30-3.35 (m, 1H), 3.2-3.3 (m, 1H), 3.19 (s, 3H), 2.43 (s, 3H), 2.3-2.4 (m, 1H), 2.0-2.2 (m, 1H) LC-MS (ESI): Method 4t R = 6.59 minutes; m / z (M+1) = 565.3

[0208] The following compounds were prepared according to the method of Example 47, starting from the corresponding protected intermediate. [Table 36]

[0209] Example 49: Preparation of (S)-4-methyl-3-(1-(2-(methylamino)pyrimidin-5-yl)pyrrolidin-3-yl)-N-(3-(trifluoromethyl)phenyl)benzamide [ka] Intermediate 41 (60 mg, 0.108 mmol) was dissolved in 1 mL of HCl 4M in dioxane and stirred at rt. The crude was evaporated to dryness, dissolved in 1 mL MeOH (+20% DMSO) and purified by preparative HPLC. The relevant fractions were collected, loaded onto an SCX column, washed with MeOH and the product was eluted with methanolic ammonia. The solution was dried to give the desired product (13.2 mg, 0.029 mmol, 10.1% yield). 1 H NMR (ACN-d3, 400 MHz) δ 8.88 (br s, 1H), 8.16 (s, 1H), 7.9-7.9 (m, 3H), 7.84 (d, 1H, J=2.0 Hz), 7.71 (dd, 1H, J=2.0, 7.9 Hz), 7.55 (t, 1H, J=8.0 Hz), 7.43 (d, 1H, J=7.7 Hz), 7.35 (d, 1H, J=7.9 Hz), 5.00 (br d, 1H, J=4.2 Hz), 3.8-3.9 (m, 1H), 3.6-3.7 (m, 1H), 3.3-3.5 (m, 3H), 2.84 (d, 3H, J=5.0 Hz), 2.48 (s, 3H), 2.4-2.5 (m, 1H), 2.1-2.2 (m, 1H) LC-MS ESI): Method 4t R = 7.36 minutes; m / z (M+1) = 456.3

[0210] Example 50: Preparation of (S)-3-(1-(6-aminopyridin-3-yl)pyrrolidin-3-yl)-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide [ka] Intermediate 38 (89 mg, 0.189 mmol), ammonium chloride (364 mg, 6.81 mmol) and iron (127 mg, 2.270 mmol) were dissolved in 2-propanol (2 mL) and water (1.0 mL). The reaction mixture was stirred for 1 h at 80° C. Then it was diluted with EtOAc and added NaHCO 3 It was washed with saturated solution. The organic phase was evaporated under reduced pressure. Purification by reversed phase FCC gave the desired product (24 mg, 0.054 mmol, 29%). 1 H NMR (acetone, 400 MHz) δ 9.72 (br s, 1H), 8.25 (s, 1H), 8.0-8.0 (m, 2H), 7.79 (br d, 1H, J=8.1 Hz), 7.55 (t, 1H, J=8.0 Hz), 7.47 (d, 1H, J=2.4 Hz), 7.40 (br d, 1H, J=7.7 Hz), 7.34 (d, 1H, J=7.9 Hz), 6.91 (dd, 1H, J=2.7, 8.9 Hz), 6.50 (d, 1H, J=8.8 Hz), 4.59 (br s, 1H), 3.8-3.9 (m, 1H), 3.61 (t, 1H, J=8.2 Hz), 3.47 (dt, 1H, J=3.4, 8.5 Hz), 3.3-3.4 (m, 1H), 3.27 (t, 1H, J=8.3 Hz), 2.49 (s, 3H), 2.4-2.5 (m, 1H), 2.1-2.2 (m, 1H) LC-MS ESI): Method 4t R = 6.0 min; m / z (M+1) = 441.3

[0211] Example 51: Preparation of (S)-3-(1-(2-acetamidopyrimidin-5-yl)pyrrolidin-3-yl)-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide [ka] The compound of Example 50 (40 mg, 0.091 mmol) was dissolved in DCM (3 ml), then DIPEA (0.047 ml, 0.272 mmol) and acetyl chloride (7.11 mg, 0.091 mmol) were added. The mixture was stirred at rt overnight. The solution was saturated with NH 4 Cl solution, saturated NaHCO 3 The organic layer was washed with Na 2 SO 4 The crude product was purified by reverse phase FCC, then the relevant fractions were basified to pH 8-9 and the product was extracted with DCM to give the title compound (11.1 mg, 0.023 mmol, 25.3% yield). 1 H NMR (ACN-d3, 400 MHz) δ 8.90 (br s, 1H), 8.33 (br s, 1H), 8.16 (s, 1H), 8.04 (s, 2H), 7.91 (br d, 1H, J=8.1 Hz), 7.84 (s, 1H), 7.73 (br d, 1H, J=7.7 Hz), 7.55 (t, 1H, J=8.0 Hz), 7.3-7.5 (m, 2H), 3.3-3.9 (m, 5H), 2.49 (s, 3H), 2.4-2.5 (m, 1H), 2.2-2.3 (m, 1H), 2.14 (s, 3H) LC-MS ESI): Method 4t R = 6.6 minutes; m / z (M+1) = 484.3

[0212] Example 52: Preparation of (S)-4-methyl-3-(1-(5-(1-methyl-1H-pyrazol-4-yl)pyridin-3-yl)pyrrolidin-3-yl)-N-(3-(trifluoromethyl)phenyl)benzamide [ka] Add K to the vial 3 PO 4 (211 mg, 0.993 mmol), the compound of Example 62 (167 mg, 0.331 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (152 mg, 0.73 mmol), Pd-170 (11.15 mg, 0.017 mmol), THF (2 ml) and water (2.0 ml). The solution was back-filled with Ar and then the solution was stirred for 1 h at 50° C. The solution was filtered, diluted with EtOAc and added NaHCO 3 Wash with saturated solution. 1 H NMR (DMSO-d 6 , 400 MHz) δ 10.38 (s, 1H), 8.1-8.2 (m, 2H), 8.07 (d, 1H, J=1.8 Hz), 8.00 (d, 1H, J=8.6 Hz), 7.93 (d, 1H, J=1.8 Hz), 7.89 (s, 1H), 7.81 (d, 1H, J=2.9 Hz), 7.77 (dd, 1H, J=1.8, 7.9 Hz), 7.55 (t, 1H, J=8.0 Hz), 7.40 (d, 1H, J=7.7 Hz), 7.35 (d, 1H, J=8.1 Hz), 7.07 (t, 1H, J=2.2 Hz), 3.82 (s, 3H), 3.7-3.8 (m, 2H), 3.5-3.6 (m, 1H), 3.4-3.5 (m, 1H), 3.3-3.4 (m, 1H), 2.45 (s, 3H), 2.3-2.4 (m, 1H), 2.2-2.3 (m, 1H) LC-MS ESI): Method 4t R = 6.4 minutes; m / z (M+1) = 506.4

[0213] Example 54 and Example 55: Preparation of 4-(3-(2-methyl-5-((3-(trifluoromethyl)phenyl)carbamoyl)phenyl)pyrrolidin-1-yl)picolinamide - First and second eluting isomers [ka] The isomers of the racemic mixture of Example 53 (10 mg) were separated by chiral FC. The combined fractions of single enantiomers were then evaporated to near dryness using a rotary evaporator and then in a vacuum oven to give the two single enantiomers.

[0214] Example 54 First eluting isomer (1.0 mg, 2.10 μmol, 10%). LC-MS (ESI): Method 8t R = 4.95 minutes; m / z (M+1)= 469.4 Chiral Analysis (SFC Method 10): R 2.36 minutes, ee 100% 1 H NMR (400 MHz, DMSO) δ 10.41 (s, 1H), 8.19 (s, 1H), 8.15 (d, J=5.8 Hz, 1H), 8.03 (d, J=8.6 Hz, 1H), 7.97 (d, J=3.3 Hz, 1H), 7.93 (d, J=1.5 Hz, 1H), 7.79 (dd, J=1.8, 7.8 Hz, 1H), 7.58 (t, J=7.8 Hz, 1H), 7.49 - 7.42 (m, 2H), 7.38 (d, J=8.1 Hz, 1H), 7.21 (d, J=2.5 Hz, 1H), 6.68 (dd, J=2.5, 5.8 Hz, 1H), 3.86 - 3.78 (m, 2H), 3.65 - 3.60 (m, 1H), 3.53 - 3.42 (m, 2H), 2.47 (s, 3H), 2.45 - 2.37 (m, 1H), 2.26 - 2.19 (m, 1H)

[0215] Example 55 The second eluting isomer (1.0 mg, 2.10 μmol, 10%). LC-MS (ESI): Method 9t R= 3.80 min; m / z (M+1) = 469.5 Chiral analysis (SFC method 10): t R 3.61 min, ee 99.78% 1 H NMR (400 MHz, DMSO) δ 10.41 (s, 1H), 8.19 (s, 1H), 8.15 (d, J = 5.6 Hz, 1H), 8.02 (d, J = 8.3 Hz, 1H), 7.97 (d, J = 2.8 Hz, 1H), 7.93 (d, J = 1.5 Hz, 1H), 7.79 (dd, J = 1.6, 7.7 Hz, 1H), 7.59 (t, J = 8.0 Hz, 1H), 7.49 - 7.42 (m, 2H), 7.38 (d, J = 7.8 Hz, 1H), 7.21 (d, J = 2.5 Hz, 1H), 6.67 (dd, J = 2.4, 5.7 Hz, 1H), 3.87 - 3.78 (m, 2H), 3.68 - 3.40 (m, 3H), 2.47 (s, 3H), 2.45 - 2.35 (m, 1H), 2.26 - 2.19 (m, 1H)

[0216] Example 56: Preparation of (S)-5-(3-(2-methyl-5-((4-(morpholinomethyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)pyrrolidin-1-yl)nicotinamide

Chemical Structure

Chemical Structure

[0217] Step 2: Ethyl 3-(1-benzylpyrrolidin-3-yl)-4-methylbenzoate (Intermediate 43) [ka] Intermediate 43 was prepared by the method of Intermediate 11 starting from Intermediate 42 (78.4 g, 412 mmol) and N-benzyl-1-methoxy-N-((trimethylsilyl)methyl)methanamine (73.4 g, 309 mmol). The solvent was removed under reduced pressure and the crude was used in the next step without further purification. LC-MS (ESI): (Method 2) t R = 1.07 min; m / z (M+1) = 324.0

[0218] Step 3: Ethyl 4-methyl-3-(pyrrolidin-3-yl)benzoate (Intermediate 44) [ka] A 1 L reactor was purged with nitrogen and charged with palladium / C 10 (50% wet) (21.88 g, 10.28 mmol). The system was purged once more with nitrogen and placed under reduced pressure. A solution of intermediate 43 (133 g, 411 mmol) in EtOH (500 ml) was then added. The solution was then placed under a hydrogen atmosphere (4 bar), warmed to 60° C. and stirred for 8 h. The reaction mixture was filtered through Celite, concentrated and the crude was then purified by hexane distillation. 2 The mixture was dissolved in 0 and extracted with 1N HCl in quantitative yield. LC-MS (ESI): (Method 2) t R = 0.69 min; m / z (M+1) =233.9 1 H NMR (chloroform-d, 400 MHz) δ 7.91 (s, 1H), 7.79 (dd, 1H, J=1.5, 7.9 Hz), 7.22 (d, 1H, J=7.6 Hz), 4.37 (q, 2H, J=7.0 Hz), 3.4-3.5 (m, 1H), 3.4-3.4 (m, 1H), 3.31 (ddd, 2H, J=4.6, 8.6, 11.0 Hz), 3.17 (td, 1H, J=7.6, 11.0 Hz), 2.93 (dd, 1H, J=8.1, 10.7 Hz), 2.42 (s, 3H), 2.2-2.3 (m, 1H), 1.9-2.0 (m, 1H), 1.40 (t, 3H, J=7.1 Hz)

[0219] Step 4: tert-Butyl 3-(5-(ethoxycarbonyl)-2-methylphenyl)pyrrolidine-1-carboxylate (Intermediate 45) [ka] Intermediate 45 was prepared starting from Intermediate 44 (20.35 g, 87 mmol) following the method of Intermediate 13. After purification by silica gel FCC the title compound (24.5 g, 73.5 mmol, 84% yield) was obtained. LC-MS (ESI): (Method 1) t R = 1.35 minutes; m / z (M+1-tBu): 277.9

[0220] Step 5: tert-Butyl (R)-3-(5-(ethoxycarbonyl)-2-methylphenyl)pyrrolidine-1-carboxylate (Intermediate 46a) and tert-butyl (S)-3-(5-(ethoxycarbonyl)-2-methylphenyl)pyrrolidine-1-carboxylate (Intermediate 46b) Intermediate 45 (20.1 g, 0.060 mol) as a racemic mixture was dissolved in MeOH to 90 mg / mL and then purified by SFC according to Method 11. The combined first eluting (Intermediate 46a) and second eluting (Intermediate 46b) fractions were then evaporated to near dryness using a rotary evaporator. The resulting solid was then transferred with DCM to a final vessel, which was placed under a stream of compressed air at 35° C. and then kept in a vacuum oven at 35° C. and 5 mbar until the weight was constant.

[0221] First eluting enantiomer (intermediate 46a) [ka] Amount: 9.6g Chiral Analysis (SFC Method 12): R 1.238 min, ee 100% LC-MS (ESI): Method 7t R = 1.723 minutes; m / z (M+1-tBu)= 278.2

[0222] The second eluting enantiomer (Intermediate 46b) [ka] Amount: 9.2g Chiral Analysis (SFC Method 12): R 1.562 min, ee 100% LC-MS (ESI): Method 7t R = 1.722 minutes; m / z (M+1-tBu)= 278.2

[0223] Intermediates 14 and 15 were synthesized under non-racemic conditions starting from intermediates 46a and 46b, respectively. The absolute configurations of intermediates 14 and 15 were confirmed by IR and VCD spectroscopy (see Examples 15 and 16), thereby unambiguously determining the absolute configurations of intermediates 46a and 46b.

[0224] Step 5: Ethyl (S)-4-methyl-3-(pyrrolidin-3-yl)benzoate (Intermediate 47) [ka] Intermediate 47 was prepared following the method of Intermediate 16 starting from Intermediate 46b (4.800 g, 14.40 mmol) to give the desired product (3.40 g, 14.57 mmol, 100% yield). LC-MS (ESI): Method 1 t R = 0.5 min; m / z (M+1)= 234.1

[0225] Step 6: Ethyl (S)-3-(1-(5-cyanopyridin-3-yl)pyrrolidin-3-yl)-4-methylbenzoate (Intermediate 48) [ka] Intermediate 48 was prepared according to Example 5, step 6 starting from intermediate 47 (3.4 g, 14.57 mmol) and 5-bromonicotinonitrile (4.00 g, 21.86 mmol). Purification by FCC (0-40% EtOAc in heptane) afforded the title compound (3.3 g, 9.84 mmol, 68% yield). LC-MS (ESI): Method 1 t R = 1.2 minutes; m / z (M+1)= 336.0

[0226] Step 7: Ethyl (S)-3-(1-(5-carbamoylpyridin-3-yl)pyrrolidin-3-yl)-4-methylbenzoate (Intermediate 49) [ka] Intermediate 49 was prepared starting from Intermediate 48 (2 g, 5.96 mmol) according to the method of Example 17. The reaction was quenched with water, then the precipitated white solid was collected by filtration, washed with water, and dried overnight to give the desired product (2.14 g, 6.06 mmol, 100% yield). 1 H NMR (400 MHz, DMSO-d6 ) δ ppm 1.23 (t, J=7.13 Hz, 3 H) 2.04 - 2.17 (m, 1 H) 2.36 - 2.44 (m, 1 H) 2.46 (s, 3 H) 3.34 (br d, J=2.41 Hz, 1 H) 3.41 - 3.55(m, 2 H) 3.73 - 3.82 (m, 2 H) 4.24 (q, J=7.09 Hz, 2 H) 7.33 - 7.35 (m, 1 H) 7.37 (s, 1 H) 7.45 (br s, 1H) 7.73 (dd, J=7.89, 1.75 Hz, 1 H) 7.81 (d, J=1.53Hz, 1H) 8.03 (br s, 1 H) 8.10 (d, J=2.85 Hz, 1 H) 8.32 (d, J=1.53 Hz, 1 H) LC-MS (ESI): Method 1 t R = 0.69 min; m / z (M+1)= 354.3

[0227] Step 8: (S)-5-(3-(2-methyl-5-((4-(morpholinomethyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)pyrrolidin-1-yl)nicotinamide (Example 56) 4-(Morpholin-4-ylmethyl)-3-(trifluoromethyl)aniline (184 mg, 0.7 mmol) was dissolved in dry THF (5 ml) under nitrogen and the mixture was stirred at -78°C for 15 minutes, then a 2.5M solution of butyllithium in hexane (0.191 ml, 0.478 mmol) was added dropwise over 5 minutes and the reaction was stirred for 1 hour at -78°C. A solution of intermediate 49 (50 mg, 0.14 mmol) in THF (5 ml) was added dropwise over 10 min, the temperature was raised to rt and the reaction was stirred for 1 h. Water was added to quench the reaction and the solvent was evaporated under reduced pressure. The solid was dissolved in EtOAc and NH 4The organic phase was evaporated under reduced pressure. After purification by FCC, the relevant fractions were combined, loaded onto an Isolute SCX-2 cartridge, washed with MeOH and the product was eluted with 2N methanolic ammonia. The residue was concentrated under reduced pressure to give the title compound (16 mg, 0.028 mmol, 20% yield). 1 H NMR (DMSO-d 6 , 400 MHz) δ 10.35 (s, 1H), 8.3-8.3 (m, 1H), 8.13 (d, 1H, J=2.0 Hz), 8.07 (d, 1H, J=2.6 Hz), 7.9-8.0 (m, 2H), 7.90 (s, 1H), 7.74-7.78 (m, 1H), 7.68 (d, 1H, J=8.6 Hz), 7.42 (s, 1H), 7.3-7.4 (m, 2H), 3.7-3.8 (m, 2H), 3.3-3.6 (m, 13H), 2.1-2.4 (m, 5H) LC-MS (ESI): Method 4t R = 4.28 minutes; m / z (M+1)= 568.3

[0228] The following compounds were prepared by the method of Example 56, Step 8, starting from the corresponding amine. [Table 37]

[0229] Example 58: Preparation of (S)-5-(3-(5-((4-((dimethylamino)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)-2-methylphenyl)pyrrolidin-1-yl)nicotinamide [ka] Step 1; (S)-3-(1-(5-cyanopyridin-3-yl)pyrrolidin-3-yl)-N-(4-((dimethylamino)methyl)-3-(trifluoromethyl)phenyl)-4-methylbenzamide (Intermediate 50 / Example 65) [ka] 4-[(Dimethylamino)methyl]-3-(trifluoromethyl)aniline (195 mg, 0.89 mmol) was dissolved in dry THF (2 ml). The vial was purged with argon and back-filled. A solution of LiHMDS (1.118 ml, 1.118 mmol) was then added and the mixture was stirred at rt for 6 h. Intermediate 48 (150 mg, 0.447 mmol) was then dissolved in THF (2 ml) and added to the solution. The resulting solution was stirred at rt. The solvent was evaporated and the resulting solid was dissolved in EtOAc and H 2 O or NaHCO 3 Washing with saturated solution. Purification by FCC gave the desired product (126 mg, 0.25 mmol, 55% yield). LC-MS (ESI): Method 1 R = 0.75 min; m / z (M+1) = 508.4

[0230] Step 2: (S)-5-(3-(5-((4-((dimethylamino)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)-2-methylphenyl)pyrrolidin-1-yl)nicotinamide (Example 58) Example 58 was prepared starting from intermediate 50 (126 mg, 0.25 mmol) following the preparation of intermediate 49. After precipitation from water and washing with ethyl ether, the desired product (77 mg, 0.147 mmol, 59% yield) was obtained. 1H NMR (DMSO-d6, 400 MHz) δ 10.35 (s, 1H), 8.28 (s, 1H), 8.13 (s, 1H), 8.07 (d, 1H, J=2.4 Hz), 8.0-8.0 (m, 2H), 7.91 (s, 1H), 7.76 (d, 1H, J=7.9 Hz), 7.65 (d, 1H, J=8.3 Hz), 7.43 (br s, 1H), 7.34 (d, 1H, J=7.9 Hz), 7.31 (br s, 1H), 3.76 (br d, 2H, J=4.4 Hz), 3.5-3.6 (m, 1H), 3.3-3.5 (m, 4H), 2.44 (s, 3H), 2.4-2.4 (m, 1H), 2.2-2.2 (m, 1H), 2.14 (s, 6H) LC-MS (ESI): Method 4t R = 4.57 minutes; m / z (M+1)= 526.3

[0231] Example 59: Preparation of (S)-3-(1-(5-acetamidonicotinoyl)pyrrolidin-3-yl)-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide [ka] Example 59 was prepared by the method of Intermediate 3 starting from Intermediate 17 (100 mg, 0.287 mmol) and 5-acetamidonicotinic acid (130 mg, 0.722 mmol). The residue was purified by reverse phase FCC, loaded onto an SCX column, washed with MeOH and eluted with methanolic ammonia to give the desired product (29.2 mg, 0.057 mmol, 20% yield). 1H NMR (ACN-d3, 600 MHz) δ 8.8-8.9 (m, 2H), 8.59 (dd, 2H, J=2.1, 8.2 Hz), 8.47 (br s, 2H), 8.36 (s, 2H), 8.17 (s, 1H), 8.15 (s, 1H), 8.10 (br s, 2H), 7.87 (br d, 2H, J=8.2 Hz), 7.79 (s, 1H), 7.74 (s, 1H), 7.65 (d, 1H, J=7.8 Hz), 7.61 (d, 1H, J=8.0 Hz), 7.48 (dt, 2H, J=4.4, 7.9 Hz), 7.3-7.4 (m, 2H), 7.28 (d, 1H, J=7.6 Hz), 7.22 (d, 1H, J=7.9 Hz), 3.96 (dd, 1H, J=7.6, 12.0 Hz), 3.7-3.8 (m, 3H), 3.5-3.6 (m, 6H), 2.40 (s, 3H), 2.29 (s, 3H), 2.2-2.3 (m, 4H), 1.98 (s, 3H), 2.01 (s, 3H) LC-MS (ESI): Method 4t R = 6.25 minutes; m / z (M+1)= 511.2

[0232] The following compounds were prepared according to the method of Example 59 starting from the corresponding carboxyl groups. [Table 38]

[0233] Aziridinyl (C1) instead of the pyrrolidinyl ring or -CH between the pyrrolidinyl ring and the group A 2 A comparative newly synthesized compound having a -linker (C2) was prepared as follows. Compound C1 4-Methyl-3-(1-(pyridin-3-yl)aziridin-2-yl)-N-(3-(trifluoromethyl)phenyl)benzamide [ka] Step 1: 3-Formyl-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide (Intermediate 20) [ka] Intermediate 10 (4.00 g, 13.10 mmol) was dissolved in EtOH (50 ml) and then ozone (0.629 g, 13.10 mmol) was introduced at -78 °C. After disappearance of SM by LC-MS, AcOH (3.23 ml, 56.3 mmol) and zinc (0.857 g, 13.10 mmol) were added and the reaction mixture was warmed to rt and stirred for 1 h. After filtration and solvent removal, DCM and H 2 O was added. The organic layer was separated and 2 SO 4 The crude product was purified by FCC (gradient A:B 100:0 to 50:50, eluent A: n-heptane eluent B: acetone) to give the title compound (2.3 g, 7.49 mmol, 57.1% yield).

[0234] Step 2: (E)-4-Methyl-3-((pyridin-3-ylimino)methyl)-N-(3-(trifluoromethyl)phenyl)benzamide (Intermediate 21) [ka] 3-Aminopyridine and intermediate 20 (50 mg, 0.163 mmol) were dissolved in dry DCM (2.0 ml) and 2 drops of acetic acid (0.00 mmol) were added. Molecular sieves 4A were then added and the reaction was stirred at 80° C. for 48 h. The crude was filtered and the solvent was evaporated under reduced pressure to give the title compound, which was used in the next step without further purification.

[0235] Step 3: 4-Methyl-3-(1-(pyridin-3-yl)aziridin-2-yl)-N-(3-(trifluoromethyl)phenyl)benzamide (Compound C1) A solution of the ylide was prepared under nitrogen from trimethylsulfoxonium iodide (48.1 mg, 0.219 mmol), sodium hydride (5.24 mg, 0.219 mmol) and dry DMSO (3 ml). With stirring, a solution of intermediate 21 (69.8 mg, 0.182 mmol) in dry DMSO (3 ml) was added at RT, then the solution was stirred at rt for 1 h and at 60° C. for 2 h. The crude was purified by direct phase FCC (gradient A:B 100:0→60:40, eluent A: n-heptane eluent B: acetone) to give the title compound (58 mg, 0.146 mmol, 42.6%). 1 H NMR (CAN-d3, 400 MHz) δ 8.95 (br s, 1H), 8.44 (d, J=2.6 Hz, 1H), 8.23 ​​(dd, J=1.3, 4.8 Hz, 1H), 8.16 (s, 1H), 7.98 (d, J=1.5 Hz, 1H), 7.93 (br d, J=8.1 Hz, 1H), 7.80 (dd, J=1.8, 7.9 Hz, 1H), 7.55 (t, J=8.0 Hz, 1H), 7.4-7.5 (m, 2H), 7.37 (d, J=7.9 Hz, 1H), 7.25 (dd, J=4.6, 8.1 Hz, 1H), 3.41 (dd, J=3.3, 6.6 Hz, 1H), 2.6-2.6 (m, 1H), 2.51 (s, 3H), 2.37 (dd, J=0.7, 3.3 Hz, 1H) LC-MS (ESI): Method 3t R = 7.65 minutes; m / z (M+1) = 398.2

[0236] Compound C2: 4-Methyl-3-(1-(pyridin-3-ylmethyl)pyrrolidin-3-yl)-N-(3-(trifluoromethyl)phenyl)benzamide [ka] Intermediate 12 (50 mg, 0.144 mmol) was dissolved in DMF (1 ml) then 3-(bromomethyl)pyridine hydrobromide (37.0 mg, 0.215 mmol) and TEA (0.080 ml, 0.574 mmol) were added. The reaction was stirred at rt for 4 h. The crude was directly purified by reverse phase FCC (gradient A:B 100:0 to 0:100. Eluent A:H 2 O:ACN:HCOOH 95:5:0.1 Eluent B:H 2 The mixture was purified with 5:95:0.1 hexanes (5:O:ACN:HCOOH). Relevant fractions were combined, loaded onto an Isolute SCX-2 cartridge, washed with MeOH and the product was eluted with 2N methanolic ammonia. The residue was concentrated under reduced pressure to give the title compound (13 mg, 0.030 mmol, 20.6% yield). 1 H NMR (acetone, 400 MHz) δ 7.21 - 8.69 (m, 12H), 3.7-4.3 (m, 3H), 2.99-3.33 (m, 4H), 2.4-2.5 (m, 2H), 2.40 (s, 3H) LC-MS (ESI): Method 3t R = 5.25 minutes; m / z (M+1) = 440.2

[0237] Pharmacological activity of the compounds of the present invention In vitro assays Binding assays DDR1 and DDR2 binding assays were performed using Life Technologies LanthaScreen TMThe Europium Kinase Binding assay was used. Compounds were incubated with 5 nM DDR1 (Carna Biosciences) or 5 nM DDR2 (Life Technologies) for 1 h at rt in white 384-well OptiPlates (PerkinElmer) containing 20 nM or 10 nM Kinase Tracer 178, respectively, and 2 nM Europium-labeled anti-GST antibody (Life Technologies) in assay buffer (50 mM HEPES pH 7.5, 10 mM MgCI2, 1 mM EGTA and 0.01% BRIJ35). Fluorescence emission 665 nm / 615 nm ratios after excitation at 340 nm were obtained using a Tecan Spark 20M plate reader. IC 50 Values ​​were obtained in GraphPad Prism 7.0 software using a four-parameter model: log(inhibitor) vs. response. IC 50 The value was calculated using the Cheng-Prusoff equation (Ki=IC 50 Conversion to Ki was performed using / (1+[tracer] / Kd).

[0238] The results for individual compounds are shown in Table 5 below, where compounds are ranked by strength of binding (nM) with respect to inhibitory activity against DDR1 and DDR2. [Table 39] [Table 40] -:Ki >60nM +:Ki 25~60nM ++: Ki 25nM~10nM +++: Ki less than 10 nM.

[0239] As is clear, the compounds in Table 5, i.e., the compounds of the present invention, show good activity as antagonists of DDR1 and DDR2. Therefore, the compounds of the present invention can be effectively used for treating diseases, disorders or conditions associated with DDR receptors, such as fibrosis, for example, pulmonary fibrosis, idiopathic pulmonary fibrosis (IPF), liver fibrosis, renal fibrosis, ocular fibrosis, cardiac fibrosis, arterial fibrosis and systemic sclerosis.

[0240] Comparative Compound Compounds C1 and C2 were tested in the same binding assay as above. [Table 41] As shown in Table 5, the compounds of the present invention have binding affinities for the DDR1 and DDR2 receptors, ranked by a Ki of less than 60 nM, with most compounds being less than 25 nM or less than 10 nM, whereas comparative compounds C1 have binding affinities for the DDR1 receptor of greater than 170 nM and C2 of 571 nM, and for the DDR2 receptor of greater than 300 nM and 764 nM for C1.

[0241] These data show that, contrary to comparative compound C1, which is characterized by having an aziridinyl instead of a pyrrolidinyl ring, the presence of the pyrrolidinyl ring in the compounds of the present invention unexpectedly and significantly enhances the inhibitory activity against the DDR1 and DDR2 receptors.

[0242] As is further apparent, the -CH 2 Contrary to the comparative compound C2, which is characterized by a linker, the absence of such a linker in the compounds of the present invention unexpectedly and significantly enhances the inhibitory activity against the DDR1 and DDR2 receptors.

Claims

1. Formula (I) [Formula 1] [During the ceremony, Y is absent or -C(O)-; R 1 Ha-(C 1 -C 6 ) alkylene-NR A R B or hydrogen; R 3 Ha-(C 1 -C 4 ) alkyl; A is A1, A2, A3 [chemical 2] and bicyclic heteroaryl B, where * indicates the point of attachment to Y and B is R 2 is replaced by R 2 is H or halogen, cyano, -NR A R B , -C(O)NR A R B , -C(O)NR C -(C 1 -C 6 ) alkylene-NR A R B , -C(O)NR C -(C 1 -C 6 ) Alkylene-OR A , -NR A C(O)R B , -OR A , -NR C -(C 1 -C 6 ) Alkylene-OR A , -NR C -(C 1 -C 6 ) alkylene-NR A R B , -C(O)NR A -heterocycloalkyl, heterocycloalkyl, -NR A -heteroaryl, -(C 1-C 6 ) alkylene-heterocycloalkyl, -(C 1 -C 6 ) Alkylene-OR A , -O-(C 1 -C 6 ) alkylene-NR A R B , -O-(C 1 -C 6 ) Alkylene-OR A , -O-(C 1 -C 6 ) alkylene-heterocycloalkyl, -(C 1 -C 6 ) haloalkyl and -(C 1 -C 6 ) alkyl; R A , R B and R C is independent - (C 1 -C 6 ) alkyl or hydrogen; Or R A and R B may be taken together with the nitrogen to which they are attached to form a heterocycloalkyl; And here, R 2 Each heterocycloalkyl or heteroaryl is hydrogen, halogen, -(C 1 -C 6 ) alkyl, -(C 1 -C 6 ) haloalkyl, -(C 1 -C 6 ) Alkylene-OR A , -OR A , -O-(C 1 -C 6 ) alkylene-NR A R B and -O-(C 1 -C 6 ) Alkylene-OR A and is substituted with one or more, preferably 1 to 3, substituents independently selected from the group consisting of: and pharma- ceutically acceptable salts thereof.

2. R 1 is hydrogen, R 3 is methyl; [C3] [During the ceremony, Y is absent or -C(O)-; A is A1, A2 and A3 [C4] is selected from the group consisting of where * indicates the point of attachment to Y; and R 2 is H or a halogen atom, cyano, -C(O)NH 2 , -C(O)NH-(C 1 -C 6 ) alkyl, —C(O)NH—(C 1 -C 6 ) alkylene-NR A R B , -C(O)NH-(C 1 -C 6 ) Alkylene-OR A , -NHC(O)R B , -O-(C 1 -C 6 ) alkyl, -NH-(C 1 -C 6 ) Alkylene-OR A , —C(O)NH-heterocycloalkyl, heterocycloalkyl, —(C 1 -C 6 ) alkylene-heterocycloalkyl and —O—(C 1 -C 6 )alkylene-heterocycloalkyl, each of which optionally has one or more -(C 1 -C 6 ) alkyl substituted; R A Ha-(C 1 -C 6 ) alkyl; R B Ha-(C 1 -C 6 ) alkyl.

2. A compound of formula (I) according to claim 1 and its pharma- ceutically acceptable salts.

3. Y does not exist and A is A1 [C5] 3. A compound of formula (I) according to claim 1 or claim 2, wherein

4. Y is -C(O)- and A is A1 [C6] 3. A compound of formula (I) according to claim 1 or claim 2, wherein

5. Y does not exist and A is A2 [C7] 3. A compound of formula (I) according to claim 1 or claim 2, wherein

6. Y does not exist and A is A3 [C8] 3. A compound of formula (I) according to claim 1 or claim 2, wherein

7. Y does not exist and A is R 2 2. The compound of formula (I) of claim 1, which is a bicyclic heteroaryl substituted with:

8. A compound of formula (I) according to claim 1 or claim 2 selected from at least one of the following: N-methyl-4-(3-(2-methyl-5-((3-(trifluoromethyl)phenyl)carbamoyl)phenyl)pyrrolidin-1-yl)picolinamide (Example 1); 4-Methyl-3-(1-(pyridin-3-yl)pyrrolidin-3-yl)-N-(3-(trifluoromethyl)phenyl)benzamide (Example 2); 3-(1-(5-methoxypyridin-3-yl)pyrrolidin-3-yl)-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide (Example 3); 3-(1-(5-cyanopyridin-3-yl)pyrrolidin-3-yl)-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide (Example 4); 4-Methyl-3-(1-(5-(2-morpholinoethoxy)pyridin-3-yl)pyrrolidin-3-yl)-N-(3-(trifluoromethyl)phenyl)benzamide (Example 5); 4-Methyl-3-(1-(5-(2-(4-methylpiperazin-1-yl)ethoxy)pyridin-3-yl)pyrrolidin-3-yl)-N-(3-(trifluoromethyl)phenyl)benzamide (Example 6); N-(2-(dimethylamino)ethyl)-5-(3-(2-methyl-5-((3-(trifluoromethyl)phenyl)carbamoyl)phenyl)pyrrolidin-1-yl)nicotinamide (Example 7); 4-Methyl-3-(1-(5-morpholinopyridin-3-yl)pyrrolidin-3-yl)-N-(3-(trifluoromethyl)phenyl)benzamide (Example 8); N-(2-methoxyethyl)-5-(3-(2-methyl-5-((3-(trifluoromethyl)phenyl)carbamoyl)phenyl)pyrrolidin-1-yl)nicotinamide (Example 9); N-methyl-5-(3-(2-methyl-5-((3-(trifluoromethyl)phenyl)carbamoyl)phenyl)pyrrolidin-1-yl)nicotinamide (Example 10); 4-Methyl-3-(1-(5-(morpholinomethyl)pyridin-3-yl)pyrrolidin-3-yl)-N-(3-(trifluoromethyl)phenyl)benzamide (Example 11); 4-Methyl-3-(1-(5-(4-methylpiperazin-1-yl)pyridin-3-yl)pyrrolidin-3-yl)-N-(3-(trifluoromethyl)phenyl)benzamide (Example 12); 3-(1-(5-bromopyridin-3-yl)pyrrolidin-3-yl)-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide (Example 13); 4-Methyl-3-(1-nicotinoylpyrrolidin-3-yl)-N-(3-(trifluoromethyl)phenyl)benzamide (Example 14); (R)-4-methyl-3-(1-(pyridin-3-yl)pyrrolidin-3-yl)-N-(3-(trifluoromethyl)phenyl)benzamide (Example 15); (S)-4-methyl-3-(1-(pyridin-3-yl)pyrrolidin-3-yl)-N-(3-(trifluoromethyl)phenyl)benzamide (Example 16); 5-(3-(2-methyl-5-((3-(trifluoromethyl)phenyl)carbamoyl)phenyl)pyrrolidin-1-yl)nicotinamide (Example 17); (R)-5-(3-(2-methyl-5-((3-(trifluoromethyl)phenyl)carbamoyl)phenyl)pyrrolidin-1-yl)nicotinamide (Example 18); (S)-5-(3-(2-methyl-5-((3-(trifluoromethyl)phenyl)carbamoyl)phenyl)pyrrolidin-1-yl)nicotinamide (Example 19); (S)-4-methyl-3-(1-(pyrimidin-5-yl)pyrrolidin-3-yl)-N-(3-(trifluoromethyl)phenyl)benzamide (Example 20); 3-(1-(5-((2-(dimethylamino)ethyl)amino)pyridin-3-yl)pyrrolidin-3-yl)-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide (Example 21); 4-Methyl-3-(1-(5-((2-morpholinoethyl)amino)pyridin-3-yl)pyrrolidin-3-yl)-N-(3-(trifluoromethyl)phenyl)benzamide (Example 22); 3-(1-(5-(2-(dimethylamino)ethoxy)pyridin-3-yl)pyrrolidin-3-yl)-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide (Example 23); 3-(1-(2-cyanopyridin-4-yl)pyrrolidin-3-yl)-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide (Example 24); (S)—N-methyl-4-(3-(2-methyl-5-((3-(trifluoromethyl)phenyl)carbamoyl)phenyl)pyrrolidin-1-yl)picolinamide (Example 25); (S)—N-methyl-5-(3-(2-methyl-5-((3-(trifluoromethyl)phenyl)carbamoyl)phenyl)pyrrolidin-1-yl)nicotinamide (Example 26); (R)—N-methyl-4-(3-(2-methyl-5-((3-(trifluoromethyl)phenyl)carbamoyl)phenyl)pyrrolidin-1-yl)picolinamide (Example 27); (R)—N-methyl-5-(3-(2-methyl-5-((3-(trifluoromethyl)phenyl)carbamoyl)phenyl)pyrrolidin-1-yl)nicotinamide (Example 28); (S)-3-(1-(5-(2-methoxyethoxy)pyridin-3-yl)pyrrolidin-3-yl)-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide (Example 30); (S)-3-(1-(5-(4,4-difluoropiperidin-1-yl)pyridin-3-yl)pyrrolidin-3-yl)-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide (Example 31); (S)-3-(1-(5-(4,4-difluoropiperidine-1-carbonyl)pyridin-3-yl)pyrrolidin-3-yl)-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide (Example 32); (S)-4-methyl-3-(1-(5-(morpholine-4-carbonyl)pyridin-3-yl)pyrrolidin-3-yl)-N-(3-(trifluoromethyl)phenyl)benzamide (Example 33); (S)—N-(2-(dimethylamino)ethyl)-5-(3-(2-methyl-5-((3-(trifluoromethyl)phenyl)carbamoyl)phenyl)pyrrolidin-1-yl)nicotinamide (Example 34); (S)—N-(2-methoxyethyl)-5-(3-(2-methyl-5-((3-(trifluoromethyl)phenyl)carbamoyl)phenyl)pyrrolidin-1-yl)nicotinamide (Example 35); 3-((S)-1-(5-((R)-3-methoxypiperidin-1-yl)pyridin-3-yl)pyrrolidin-3-yl)-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide (Example 36); (S)-3-(1-(5-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pyridin-3-yl)pyrrolidin-3-yl)-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide (Example 37); (S)-3-(1-(5-(difluoromethyl)pyridin-3-yl)pyrrolidin-3-yl)-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide (Example 38); (S)-3-(1-(5-(2-oxa-6-azaspiro[3.4]octan-6-yl)pyridin-3-yl)pyrrolidin-3-yl)-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide (Example 39); (S)-3-(1-(5-acetamidopyridin-3-yl)pyrrolidin-3-yl)-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide (Example 40); (S)-3-(1-(2-acetamidopyridin-4-yl)pyrrolidin-3-yl)-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide (Example 41); (S)-3-(1-(1H-pyrrolo[2,3-b]pyridin-4-yl)pyrrolidin-3-yl)-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide (Example 42); (S)-4-methyl-3-(1-(pyrazolo[1,5-a]pyrimidin-6-yl)pyrrolidin-3-yl)-N-(3-(trifluoromethyl)phenyl)benzamide (Example 43); (S)-4-methyl-3-(1-(6-((1-methyl-1H-pyrazol-4-yl)amino)pyridin-3-yl)pyrrolidin-3-yl)-N-(3-(trifluoromethyl)phenyl)benzamide (Example 44); (S)-4-methyl-3-(1-(5-((1-methyl-1H-pyrazol-4-yl)amino)pyridin-3-yl)pyrrolidin-3-yl)-N-(3-(trifluoromethyl)phenyl)benzamide (Example 45); (S)-3-(1-(5-((1-(2-methoxyethyl)-1H-pyrazol-4-yl)amino)pyridin-3-yl)pyrrolidin-3-yl)-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide (Example 46); (S)-3-(1-(6-((1-(2-methoxyethyl)-1H-pyrazol-4-yl)amino)pyridin-3-yl)pyrrolidin-3-yl)-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide (Example 47); (S)-4-methyl-3-(1-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-5-yl)pyrrolidin-3-yl)-N-(3-(trifluoromethyl)phenyl)benzamide (Example 48); (S)-4-methyl-3-(1-(2-(methylamino)pyrimidin-5-yl)pyrrolidin-3-yl)-N-(3-(trifluoromethyl)phenyl)benzamide (Example 49); (S)-3-(1-(6-aminopyridin-3-yl)pyrrolidin-3-yl)-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide (Example 50); (S)-3-(1-(2-acetamidopyrimidin-5-yl)pyrrolidin-3-yl)-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide (Example 51); (S)-4-methyl-3-(1-(5-(1-methyl-1H-pyrazol-4-yl)pyridin-3-yl)pyrrolidin-3-yl)-N-(3-(trifluoromethyl)phenyl)benzamide (Example 52); 4-(3-(2-methyl-5-((3-(trifluoromethyl)phenyl)carbamoyl)phenyl)pyrrolidin-1-yl)picolinamide (Examples 53, 54 and 55); (S)-5-(3-(2-methyl-5-((4-(morpholinomethyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)pyrrolidin-1-yl)nicotinamide (Example 56); (S)-5-(3-(2-methyl-5-((3-(pyrrolidin-1-ylmethyl)-5-(trifluoromethyl)phenyl)carbamoyl)phenyl)pyrrolidin-1-yl)nicotinamide (Example 57); and (S)-5-(3-(5-((4-((dimethylamino)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)-2-methylphenyl)pyrrolidin-1-yl)nicotinamide (Example 58).

9. A pharmaceutical composition comprising a compound of formula (I) in admixture with one or more pharma- ceutically acceptable carriers or excipients.

10. 10. The pharmaceutical composition of claim 9 for administration by inhalation.

11. A compound of formula (I) according to any of claims 1 to 8 or a pharmaceutical composition according to claim 9 or 10 for use as a medicament.

12. 12. A compound of formula (I) or a pharmaceutical composition according to claim 11 for use in the prevention and / or treatment of a disease, disorder or condition associated with dysregulation of DDR.

13. 13. A compound of formula (I) or a pharmaceutical composition according to claim 11 or 12 for use in the prevention and / or treatment of fibrosis and / or diseases, disorders or conditions in which fibrosis is involved.

14. 14. A compound of formula (I) or a pharmaceutical composition according to claim 13 for use in the prevention and / or treatment of fibrosis, including pulmonary fibrosis, idiopathic pulmonary fibrosis (IPF), liver fibrosis, renal fibrosis, ocular fibrosis, cardiac fibrosis, arterial fibrosis and systemic sclerosis.

15. 15. A compound of formula (I) or a pharmaceutical composition according to claim 14 for use in the prevention and / or treatment of idiopathic pulmonary fibrosis (IPF).

16. Formula (VI) [C9] and compounds of formula (VII) [C10] [In the formula, R 1 and R 3 is as defined in claim 1. The compound is selected from the compounds of

17. 17. Use of a compound of formula (VI) and / or a compound of formula (VII) as defined in claim 16 in the preparation of a compound of formula (I).

18. A process for preparing a compound of formula (I) as defined in claim 1 or a pharma- ceutically acceptable salt thereof, comprising: a) Formula (V) [C11] and N-benzyl-1-methoxy-N-((trimethylsilyl)methyl)methanamine [C12] is reacted in the presence of a solvent under an acid catalyst to obtain, for example, a compound represented by the formula (VI) [C13] [In the formula, R 1 and R 3 is as defined in claim 1. and converting the compound of formula (VI) to a compound of formula (I).

19. moreover b) cleaving the compound of formula (VI) by reduction under hydrogen atmosphere in the presence of a Pd catalyst to give a benzyl group, e.g. [C14] and c) a compound of formula (VII) and a carboxylic acid compound of formula (VIII) or a fluoride compound of formula (IX) or a bromide compound of formula (X) [C15] (wherein A is as defined in claim 1). to obtain, for example, a compound of formula (I) 20. The method of claim 18, comprising the steps of: